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Pneumocystis pneumonia (PCP) is an important cause of morbidity and mortality amongst HIV-
infected children in Africa. Definitive diagnostic resources for PCP in Africa are limited due to 
their expense and technical difficulty, however recognising and treating children at risk is 
essential. As management decisions for children with pneumonia are made primarily on a 
clinical basis in many African regions, it is important to attempt to define a valid clinical 
diagnostic technique for PCP that could be used by clinicians to determine the use of correct 
empirical antibiotic therapy. The objectives of this study were to identify clinical features 
( associated with PCP in HI V-infected children hospitalised with pneumonia, to determine the 
combination of features that best predicts PCP in these children, and to calculate the diagnostic 
accuracy of these features. 
Methods 
This study was a re-analysis of a database of a prospective study. Consecutive children below ten 
years of age, with a primary diagnosis of pneumonia or severe pneumonia, and who were known 
to be HIV-infected or were suspected of having HIV infection, were included prospectively over 
a 12 month period. Clinical data and diagnostic testing for PCP were obtained on admission. Bi­
and multivariate analysis of associations of the clinical variables with PCP were performed using 
logistic regression, to identify the combination of variables that best predicted PCP. The 
diagnostic accuracy of the best predicted features were calculated. 
Results 
151 children were enrolled, of whom 15 were diagnosed with PCP. Four clinical variables were 
found to be independently associated with a diagnosis of PCP. These were: age < 6 months (OR 












53.2; p =0.018), arterial percentage haemoglobin oxygen saturation ~ 92 (OR 5.1; 95% CI 1.0 
26.1; p = 0.052) and absence of history of vomiting at presentation (OR 11.2; 95% CI 1.9 68.0; 
P = 0.008). The sensitivity and specificity of diagnosing PCP with any two or more of the four 
clinical indicators was 1.00 (95% CI 0.74 - 1.00) and 0.49 (95% CI 0.39 - 0.59) respectively; 
with three or more of the indicators the sensitivity and specificity was 0.75 (95% CI 0.43 - 0.95) 
and 0.90 (95% CI 0.83 - 0.95) respectively. The interval likelihood ratio (iLR) associated with 
none or anyone of the indicators being present was zero, with an associated post-test probability 
of PCP of 0%. Presence of any three of the variables had an iLR of 5.0 (95% CI 2.0 - 12.5) with 
a post-test probability of PCP of 36% (95% CI 18% - 58%) in the sample. All four variables 
being present had an iLR of 36.0 (95% CI 4.4 - 96.5) with a post-test probability of PCP of 80% 
(95% CI 33% - 97%). 
Discussion 
This analysis provides preliminary evidence in the clinical prediction of PCP in HIV-infected 
children hospitalised with pneumonia, and has identified four easily measured clinical indicators 
that are independently associated with PCP. The presence of none, or anyone of the clinical 
indicators is associated with low post-test probabilities of PCP, and any three or all four 
indicators with increased probabilities. The diagnostic tool is however unable to conclusively 
identify children at the population level that do not require specific anti-pneumocystis treatment 
The measures of test diagnostic accuracy are imprecise indicating a lack of statistical power, and 
design-related biases may have influenced the results .. Further studies should be undertaken to 
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Chapter 1: Introduction 
1 INTRODUCTION AND LITERATURE REVIEW 
1.1 Background 
Pneumocystis pneumonia (PCP) caused by P. jiroveci infection (previously classified as P. 
carinii), is a common life-threatening complication of HIV infection in children. In a developed 
setting, PCP has been found to be the most frequent reason for admission of HIV -infected 
children to a paediatric intensive care unit, accounting for 45% of admissions over a ten-year 
period in the United Kingdom (Lubis 2004). The burden of PCP in HI V-infected African 
children was previously poorly described, as a result of a lack of resources to adequately 
diagnose PCP, and adult data suggesting it to be rare in the African region (Abouya 1992, 
Batungwanayo 1994). Post-mortem studies since the turn of the century have however found 
PCP to be the cause of respiratory-related deaths in 29% of HIV-infected children in Zambia, 
32% in Botswana, and 67% in Zimbabwe (Chintu 2002. Ansari 2003. Nathoo 2001). 
Investigators have used varying diagnostic methods and sample selection criteria in ante-mortem 
studies of the burden of PCP in African children. The proportion of PCP amongst HIV -infected 
children hospitalised with pneumonia has been found to be 10% in Cape Town using 
bronchoalveolar lavage (BAL) and induced sputum (IS) samples, and 11% in Malawi using 
nasopharyngeal aspirates (NPA) (Zar 2000, Graham 2000). Children with severe pneumonia as 
defined by the World Health Organization clinical criteria (WHO 1994) were found to have PCP 
in 44% and 49% of episodes in two studies from Johannesburg using IS and NPA samples 











Chapter 1: Introduction 
PCP in HIV-infected children has a high mortality, with in-hospital case-fatality rates ranging 
from 20% - 63% in Africa (Mad hi 2002, Ruffini 2002, Zar 2000, Graham 2000). Developed 
countries had similar mortality rates at earlier stages of the HIV epidemic, with reported 
mortality rates of 22% - 64% (Bye 1994, Sleasman 1993). 
In South Mrica, HIV -infected children account for 60% of children hospitalised with 
pneumonia, and 45% of patients with severe pneumonia (Zar 2001, Madhi 2002). HIV­
associated PCP is therefore a common and important cause of morbidity and mortality amongst 
children in this country. 
1.2 Diagnosis of PCP 
Histological diagnosis following percutaneous lung aspiration biopsy, is the gold standard for the 
ante-mortem identification of aetiological pathogens in pneumonia (Zar 2003). It is however an 
invasive procedure, and is associated with the risk of pneumothorax and clinical 
decompensation, especially in children with severe respiratory illness. Lower respiratory tract 
secretions obtained from BAL is considered the best alternative method of diagnosing PCP 
(Ruffini 2002, Behrman 2004), and has been shown to produce yields for PCP of 40% in a 
developed country (Gibb 1994) and 30% in Durban (McNally 2004). BAL is performed non­
bronchoscopically in infants (NB-BAL), by lavaging the distal airways with a suction catheter 
passed down the endotracheal tube, as the paediatric bronchoscope would obstruct airflow in the 
infants' airway (Morrow 2001). PCP is diagnosed from microscopy of lavage fluid, with 
visualization of cysts exhibiting typical P. jiroveci morphology using a direct monoclonal 
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reported adverse events have included arterial desaturation (63%), significant bradycardia (17%), 
and pulmonary haemorrhage (4%) (Morrow 2001, McNally 2004). The procedure also requires 
resources, including skilled personnel and specialised equipment, that are limited in most 
developing countries (Chokephaibulkit 1999, Zar 2000, Graham 2000, Chintij 2002). 
Non-invasive, simpler and inexpensive alternative diagnostic methods include obtaining IS 
samples and NPA's. IS samples are collected after administering nebulized hypertonic saline 
solution to the child, and obtaining sputum either by expectoration or suctioning. An NPA is 
obtained by instilling sterile saline into the nostrils and suctioning the nasopharynx with a 
catheter attached to a mucus trap (Zar 2001). One study only has reported the accuracy of these 
methods in the diagnosis of PCP. The sensitivity and specificity of IS was 65% and 100% 
respectively, and for NPA's found to be 38% and 80% respectively (Ruffini 2002).1 Reliable 
estimates of the diagnostic accuracy of these methods from larger studies have however not been 
produced as yet. 
Definitive diagnosis of PCP in resource-limited countries is especially difficult as BAL, and the 
laboratory infrastructure required to perform the specialised st,aining techniqpes are limited or 
unavailable. 
1 Post-mortem lung histology from limited tru-cut biopsy specimens were used as areference, 
obtained in a subset of 18 children who died (eight of whom had evidence of PCP and 10 of 
















1.3 Prevention of PCP 
Cotrimoxazole (CTX), a combination of trimethoprim (TMP) and sulfamethoxazole, is a cheap 
antibiotic with a broad spectrum of activity that is used to prevent PCP in HIV -infected children. 
Improved survival was found amongst HIV -infected infants taking CTX prophylaxis in non­
randomised retrospective cohort studies (Thea 1996, Rigaud 1994), and historical comparison 
studies have shown large reductions in the incidence of PCP in HIV-infected infants following 
the introduction of CTX prophylaxis in the United Kingdom and Thailand (Duong 1999, 
Chokephaibulkit 1999). Ruffini and colleagues (2002) found Johannesburg children with PCP to 
be less likely to have taken CTX prophylaxis compared with children with pneumonia of other 
aetiologies, in a non-randomised prospective study. Randomised control (RCT) studies of CTX 
prophylaxis in HIV-infected children had not been performed prior to 2003 (Grimwade 2003). A 
placebo-controlled RCT reported in the Lancet in November this year showed reduced mortality 
(across all age groups and baseline CD4 cell counts) and a reduced overall hospital admission 
rate in the CTX group (Chintu 2004). A specific reduction in PCP incidence could however not 
be shown, as only one trial participant (placebo group) developed PCP. The trial did also not 
include infants younger than six months of age, who are a high-risk group for developing PCP 
(Graham 2000, Madhi 2002, Chintu 2002). 
Selik and colleagues have analysed death certificate data in the United States, to report a reduced 
proportion of HIV-related childhood deaths due to PCP (from 19.0% to 7.5%) between 1987­
1999, that was temporally associated with the advent of combination antiretroviral therapy (Selik 
2003). The WHO has recently recommended the scaling up of the delivery of highly active 
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effect of HAART in HIV -infected African children have demonstrated a decreased incidence of 
pneumonia, tuberculosis, acute diarrhoea, an increase in medi,an CD4 cell percentage and mean 
weight-for-age score, and a significant drop in median viral load in children while taking 
HAART, compared with their observation period prior to HAART (Kouakoussui 2004, Fassinou 
2004, Eley 2004). Data on specific changes in the incidence of PCP are however lacking, due to 
the small number of infants that have been included in African studies. The use of HAART is not 
yet widely available in Africa, and complicated by the difficulties of diagnosing HIV-infection in 
infants, complex dosing schedules, adverse drug effects, and the cost of drugs and programme 
implementation. It is therefore unlikely at this stage to significantly affect the burden of 
childhood PCP, unless widespread HAART programmes are realised? 
1.4 Management of PCP 
The case-fatality rate of untreated children with PCP approximates 100%, therefore recognizing 
and treating children at risk is essential (Hughes 1991). The treatment of PCP differs from that 
of other organisms producing pneumonia, and is effective but has complications and potential 
adverse effects. Treatment of PCP involves the following: 
1. 	 CTX given as an intravenous loading dose of lOmglkg TMP followed by a maintenance dose 
of 20mglkglday TMP in four divided doses for 2-3 weeks. This is larger than the usual dose, 
and therefore has increased potential to produce adverse effects. Intravenous therapy is 
preferable for severely ill children, but oral treatment can be substituted for mild illness, or 
2 A full discussion on the use of HAART and CTX prophylaxis is not included, as this is not 
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once clinical improvements occur. Significant adverse events are common, occurring in 
approximately 15% of children with HIV-infection. The most common include urticarial 
rash, potential for fluid overload in ill children, and neutropenia (Behrman 2004, Zar 2001). 
Difficulties and complications associated with intravenous therapy include the high cost of 
the injectable drug, skill and resources needed to provide intravenous access, and the need for 
hospitalisation (Zar 2001). 
2. 	 Corticosteroid administration produces improved outcome in the treatment of hypoxic HI V-
infected adults with moderate to severe PCP, when administered within 72hrs of onset 
(Hughes 1991). Use of corticosteroids has also been shown to improve short-term survival, 
and reduce the need for mechanical ventilation in children with PCP from non-randomised, 
before-after studies (Bye 1994, Sleasman 1993). Randomised control studies have not been 
performed in children, however administration of corticosteroids is recommended in children 
with moderate to severe illness as part of PCP therapy. A suggested regimen is prednisone 
2mglkg for 7 days, then tapering doses over the next 10-14 days (Pickering 2000, Ruffini 
2002). Steroids have powerful immunosuppressive properties, and concern about 
cytomegalovirus (CMV) co-infection after initiating of steroids has been expressed. 
Overwhelming CMV infection in HIV-infected children occurring within weeks of initiation 
steroid therapy has been reported (McLaughlin 1995), and in a necropsy study of 16 children 
with PCP, 11 had CMV co-infection (Jeena 1997). Chintu and colleagues (2002) found 
CMV co-infection in over 40% of PCP cases. Conclusive data indicating causality due to . . 
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3. 	 Oxygen therapy should be given to hypoxic children with a room air arterial oxygen 
saturation of less than 92% (Zar 2001, b). 
It is important to accurately diagnose PCP in children, as treatment is different from that of other 
organisms causing pneumonia, timely treatment is necessary to prevent death, but it is expensive 
and has potential to produce adverse effects. A diagnostic test is required that is sensitive (Le. 
does not leave cases of PCP undetected), and reasonably specific to prevent unnecessary 
treatment of children who do not have PCP. As definitive diagnostic procedures for PCP are 
expensive and limited in most African countries, diagnoses and management decisions are made 
primarily on a clinical basis. It is therefore important to attempt to define a valid clinical 
diagnostic technique for PCP that could be used by clinicians to determine empirical antibiotic 
therapy for HIV -infected children with pneumonia. 
1.5 Clinical indicators of PCP 
Certain presenting clinical characteristics have been found in HIV-infected children hospitalised 
for PCP compared with other pneumonias: Graham and colleagues found that children with PCP 
had a significantly lower median age, median body temperature, median percentage haemoglobin 
oxygen saturation; and higher proportions had no abnormality or diffuse abnormality on 
auscultation, in comparison with children with pneumonia of other aetiologies (Graham 2000). 
Ruffini and colleagues found P. jiroveci was more likely to be isolated in children who had not 
received CTX prophylaxis (Ruffini 2002). Madhi and colleagues found children with PCP to 
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I 
 A useful clinical diagnostic tool that can be used in a resource-limited setting to distinguish HIV­
infected children with PCP from those with pneumonia of other aetiologies has however not yet 
been developed. 
1.6 	 Study Purpose, Aim and Objectives 
1.6.1 	 Purpose: 
To identify clinical criteria that may predict PCP in HIV-infected children with 
pneumonia, as opposed to pneumonia of other microbiological aetiology. 
1.6.2 	 Aim: 
To develope a diagnostic tool that can be used in a clinical setting to distinguish between 
children with and without PCP amongst HIV-infected hospitalised with pneumonia. 
1.6.3 	 Objectives: 
i) To identify clinical, x-ray, and laboratory features that may be associated with PCP in 
HIV-infected children hospitalised with pneumonia. 
ii) To determine the feature or combination of features (if any), that best predicts P. 
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1.7 Measures of diagnostic accuracy 
Investigators have reported the diagnostic accuracy ofclinical decision rules (CDR's) in two 
principal ways (McGinn 2000). The sensitivity and specificity of a rule can be calculated when 
the rule has a dichotomous ( disease/no disease) outcome, and all patients above a chosen cut-off 
are assigned the same risk of disease. If a CDR has multiple outcome levels however, the 
calculation of sensitivity and specificity involves combining categories of test results, and 
information is therefore lost. 
The usefulness of a CDR is largely determined by the accuracy with which it identifies its target 
disorder, and the interval likelihood ratio's (iLR's) of hierarchical levels oftest results are of 
greater value for informing on the accuracy of a multilevel test than are sensitivity and 
specificity (Jaeschke 1994, Mayer 2004, Buchsbaum 1991). The iLR's ofeach level ofoutcome 
of the CDR are used to calculate the post-test (or post-rule) probability of the target disorder. 
This is a function of the iLR and the pre-test (pre-rule) probability of disease, (which equals the 
prevalence or burden of disease in the population at risk, Buchsbaum 1991). The calculated 
post-test probabilities of disease may allow patients to be stratified into multiple categories of 
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2 METHODS 
Data have been collected, as detailed by Zar HJ and colleagues, in a study that aimed to compare 
the aetiology, associated features and outcome of HIV-infected children hospitalised with 
pneumonia. Data collection methods of the initial study have been summarised, and included as 
parts of sections 2.3 -2.4 (Zar 2000,2001). The current study has re-analysed data from the 
existing database. 
2.1 Study Design 
This study was a re-analysis of a database of a prospective study. 
2.2 Source population 
HIV-infected children below 10 years of age in the drainage area of the University of Cape Town 
teaching hospitals complex, who have access to healthcare, and who would make use of public 
hospital facilities. 
2.3 Setting and sample population 
The study sample comprised children admitted to four hospitals (Groote Schuur, Red Cross War 
Memorial Children's, Somerset and Conradie) between January and December 1998. 
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Children with a primary diagnosis of pneumonia or severe pneumonia, (defined as the presence 
of tachypnoea or lower chest indrawing according to World Health Organization criteria (WHO 
1994), and who were known to be HIV infected, were suspected of having HIV infection, or 
were admitted to the intensive care unit (ICU) were entered prospectively. A suspicion of HIV 
infection was based on the presence of two or more of the following: generalised 
lymphadenopathy, weight below the 3rd percentile for age, hepatomegaly, splenomegaly, oral 
candidiasis, enlarged parotids or chronic diarrhoea. 
Exclusion criteria were: 
• 	 previous admission to hospital within a month before the study 
• 	 cystic fibrosis 




• 	 Current admission to hospital for greater than 48 hours . 
2.4 Data collection 
2.4.1 Measurement of potential clinical predictors 
Eligible children were enrolled during working hours from Monday to Friday. A history and 
physical examination were performed by a doctor (intern or registrar) for each child on 
admission at the hospitals. Socio-demographic and clinical data were abstracted from the 
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Blood tests including HIV testing, bacterial culture, a complete blood count, lymphocyte 
phenotyping, and chemistry were performed. HIV infection was confirmed by two positive 
ELISA tests in children older than 18 months, or by a positive ELISA and polymerase chain 
reaction (PCR) in those younger. Chest radiography was performed on inclusion in the study. 
2.4.2 Measurement of outcome (PCP) 
Sputum was induced in non-intubated patients using nebulized hypertonic saline by a 
physiotherapist or research nurse. Physiotherapy techniques were then applied, and sputum was 
obtained either by expectoration or suctioning. A NP A was obtained by instilling four drops of 
sterile saline into the nostrils and suctioning the nasopharynx with a sterile suction catheter 
attached to a mucus trap. In intubated children, non-directed BAL was performed. 
Sputum, NPA and BAL fluid were submitted for detection of P. jiroveci. Specimens were 
liquefied, washed with sterile water, then concentrated by centrifugation. The resuspended 
deposit was used to make two smears and fixed with acetone. One smear was stained by a silver 
methenamine technique, the other was stained with monoclon~l antibody an~ scanned using a 
fluorescent microscope. A positive result on IF was regarded as visualization of five or more 
typical cysts characteristic ofP. jiroveci morphology at 100x magnification. A child was 
classified as having PCP when BAL fluid or sputum demonstrated P. jiroveci using either 
staining technique? 
3 Refer to Section 3.2 for outcome classification of children who were positive for PCP on 
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IF was performed by one medical technologist in the microbiology laboratory and silver staining 
by a medical technologist in the pathology laboratory, both situated at Red Cross Children's 
Hospital. Most of these tests were performed within 24 hours of admission, the remaining tests 
were performed at a maximum of 48 hrs after admission. The readers of these reference tests 
were blind (masked) as to the clinical symptoms of the child. 
Sputum and BAL fluid were also submitted for bacterial, viral, fungal and mycobacterial culture, 
and the NPA submitted for bacterial culture. One to three early morning gastric lavages were 
performed and specimens stained for acid·fast bacilli and cultured for M. tuberculosis. 
Children were evaluated and treated by the admitting doctor. When PCP was suspected, a 
standard treatment regime of intravenous CTX, and corticosteriods was started. Children were 
switched to oral CTX following clinical improvement for a total of 21 days of therapy. Use of 
oxygen, antibiotics or other therapy was at the discretion of the ward doctor and consultant 
paediatrician. 
2.5 Statistical analysis 
Data were entered into an Epi-Info 6 (CDC, Atlanta, USA) database during the initial study by 
two trained research nurses. For this analysis, data was imported into Stata versions 6 and 7 
(Stata corporation, Texas, USA). Continuous variables are expressed as means ± SD or as 
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Bivariate analyses of the association of clinical, laboratory and radiological features with PCP 
(as the outcome variable) were performed using logistic regression. Multiple logistic regression 
was used to determine the independent contribution of variables associated with PCP. Variables 
with a p-value of < 0.2 in the bivariate analyses were considered as eligible for inclusion in the 
multivariate analyses. The final variables were selected using forward and backward stepwise 
logistic regression, and confirmed with model-building procedures using the likelihood-ratio test 
(maximum-likelihood estimation). The best predictive clinical variables thus selected were 
combined, and the sensitivity, specificity, predictive values, and iLR's ofcombinations of these 
variables calculated, with each variable being assigned an equal weighting. Likelihood ratio 
confidence intervals were calculated as described by Simel and colleagues, 1991 (Appendix 3). 
Post-test probabilities of PCP were calculated for different prevalences ofP. jiroveci infection by 
applying Bayes' theorem (Mayer 2004, Appendix 4). An illustrative clinical decision rule 
(CDR) based on post-test probabilities of PCP was derived, and its accuracy in the sample 
assessed. 
Missing observations in the study database were approached in the regression analyses using the 
complete-subjects method, in which only subjects with all values recorded for all covariates were 
retained in the analysis (Greenland 1995). Methods such as weighted estimating equations and 
multiple imputation were not used due to their complexity and unavailability in commonly used 
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2.6 Ethical issues 
Ethical approval for this analysis was granted by the Research and Ethics Committee of the 
University of Cape Town (Ref no. 035/2004). The original data collection study was also 
approved by the University of Cape Town Research and Ethics Committee (Ref no. ERC 
183/97). Informed consent for enrolment in the study and for HIV testing was obtained from a 
parent by a research nurse. Patient names in the database were removed for the purposes of the 
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3 RESULTS 
3.1 Sample population characteristics 

One hundred and fifty one HIV-infected children were enrolled in the study, of whom 71 (47%) 

were female. Table 1 indicates demographic features, microbial pathogens isolated, and hospital 

course of children included in the sample. 

Table 1 	 Demographic features, microbial pathogens isolated, and hospital course of 
sample population (n=151) 
Age in months, median (lOR) 

Female, n (%) 

First admission, n (%) 

Newly diagnosed with HIV, n (%) 














Other viruses (HSV, RSV, parainfluenza) 

Days in hospital, median (lOR) 
ICU days, median (lOR) 
Hospital death, n (%) 















14 (9 - 20) 
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3.2 Diagnosis of PCP 
BAL was perfonned in nine children, IS samples were obtained from 139, and NPA's obtained 
from 140 children. BAL specimens were positive for PCP in six children, and IS in a further 
nine. Two children had positive NPA specimens; both were however negative on IS (neither had 
BAL), and it was concluded by the investigators of the original study to classify these children as 
negative for PCP.4 Fifteen children were therefore classified as having PCP, accounting for 
9.9% (95% CI 5.9% - 15.5%) of episodes of pneumonia in the sample. Thirteen (86.6%) children 
with PCP were younger than 6 months of age, and 43 (28.5%) children without PCP were 
younger than 6 months of age. 
Other common pathogens included S. aureus (15.0%), K. pneumoniae (10.9%), H. inJluenzae 
(8.8%),M. tuberculosis (7.4%) and cytomegalovirus (CMV, 14.3%). The median length of 
hospital stay was 14 days, and 31 (20.5%) children died while in hospital. 
Empirical broad-spectrum ant biotic treatment was commenced in 150 (99%) of children prior to 
laboratory diagnostic results being available. Specific anti-pneumocystis treatment was started 
in 25 (17%) of the sample, and in 6 (40%) of children who were later diagnosed as having PCP. 
4 The sensitivity and specificity associated with IS in the diagnosis of paediatric PCP has been 
reported as superior to that ofNPA's (Ruffini 2002, see Section 1.2). It has been suggested that 
NPA's produce a poorer reflection than IS samples of infective pathogens at the lower 
respiratory tract level (Zar 2003), as NPA's may produce increased numbers of false negative 
results by failing to detect pathogenic P. jiroveci present in the lower airways, as well as 
producing more false positive results by detection of non-pathogenic commensal P. jiroveci cysts 
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Adverse events to BAL included arterial desaturation, mild self-resolving bronchial 
haemorrhage, and bradycardia. Obtaining induced sputum produced no serious adverse events, 
however minor events that occurred included marked increase in coughing, mild epistaxis, and 
wheezing that was responsive to an inhaled bronchodilator.5 
3.3 Clinical characteristics of sample 
Clinical, laboratory and radiological features, stratified by the presence of PCP, are shown in 
table 2. Results of each subsection of the table have been ranked according to the bivariate 
p-value. 
5 Adverse events to BAL and IS were captured in separate databases that included additional 
children, that were unavailable for this analysis. BAL performed in 35 children produced a drop 
in Sa02 to below 90% in 22 (62.9%) children, mild haemorrhage in one, and bradycardia (heart 
rate below 85 beats per min) in six (17.1%) children (Morrow 2001). IS obtained from 210 
children resulted in marked increase in coughing in 8 (5.6%), mild epistaxis in 6 (4.2%), and 
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Table 2a Demographic and clinical features of the sample population stratified by the 
presence of PCP with bivariate odds ratio's of PCP 
Clinical variable 
Prior admission, n (%) 
Newly diagnosed with 
HIV, n (%) 
~ proPhy;axiS, n(%) 
Male gender, n (%) 







































































Resp. rate (breaths/min) 
Age < 6 months 63 (60-72) 55 (48-62) 1.06 1.01-1.12 
Age> 6 months 62 (50-74) 48 (40-60) 1.07 0.97-1.18 
Heart rate (beats/min) 
Age < 6 months 160 (140-180) 150 (136-160) 1.03 0.99-1.06 
Age> 6 months 130 (120-140) 130 (120-150) 0.99 0.92-1.06 
Axillarytemp (0C) 
Age < 6 months 37.0 (36.5-37.5) 36.8 (36.4-37.4) 1.21 0.59-2.46 
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Clinical variable PCP (n=15) Without PCP Odds 95% confidence 
(n=136) ratio interval (95% 
(OR) CI) of OR 
Physical exam, n (%) 
Cyanosis 8 (53.3) 35 (25.7) 3.27 1.10-9.66 0.025 
Sa02 92.5 (88-95) 94 (92-97) 0.89 0.79-0.99 0.032 
Splenomegaly 13(86.7) 85 (62.5) 0.85 -17.99 0.081 
Clubbing 
3.90 
1 (6.7) 29 (21.3) 0.26 0.03 -2.07 .0.205 
Crepitations 0.42 0.09 -2.02 0.279 
Bronchial breathing 
7 (46.7) 96 (70.5) 
3 (37.5) 47 (52.2) 0.55 0.12-2.43 0.430 
Hepatomegaly 14 (93.3) 131 (96.3) 0.53 0.59 4.90 .0.579 
Oral candida 8 (53.3) i 81 (60.0) 0.76 .0.26-2.22 0.619 
Wheeze 0.19 - 3.83 0.759 
Lower chest in drawing 
3 (33.3) 37 (38.5) 0.80 
0.8666 (40) 0.27 -4.7576 (55.9) 1.13 
Table 2b Laboratory and radiological results of the sample population stratified by 
the presence of PCP with bivariate odds ratio's of PCP 





95 % confidence 
interval (95% 
CI) of OR 
p-value 
Blood tests 
LDH (U/l) 626 (450.5-1098.5) 307 (243-465) 1.002 1.00 -1.004 0.003 
Potassium (mmol/l) 4.8 (0.6) 4.2 (0.8) 2.62 1.21- 5.68 0.014 
Haemoglobin (gldl) 9.8 (8.5-11.4) 8.8 (7.8-9.9) 1.30 1.02-1.64 0.029 
Glucose (mmol/l) 6.2 (0.8) 5.2 (1.4) 1.53 0.93-2.50 0.091 
CD4/CD8 0.4 (0.2-0.7) 0.3 (0.2-0.4) 1.67 0.91- 3.05 0.096 
Magnesium (mmol/l) 0.9 (0.1) 0.9 (0.1) 39.88 0.28 -5576 0.144 
Protein (gil) 67.5 (56-:75) 78.5 (63-88.5) 0.99 0.96-1.02 0.416 
CD4{f cells (%) 16.4 (12.7-27.6) 23.6 (14.5-38.7) 0.98 0.91-1.05 0.530 
Lymphocytes (109/1) 4.6 (3.3-8.2) 4.4 (2.5-6.7) 1.03 0.91-1.17 0.571 
Neutrophils (109/1) 6.7 (3.8-8.6) 5.6 (3.4-9.4) 0.98 0.89 -1.09 0.753 
















Radiology, n (%) 
Adenopathy * 
Diffuse alveolar pattern 
Pleural effusion 
Consolidation 






ICU admissions, n (%) 
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1.01 0.73 -1.40 0.962 
1.00 1.00 -1.00 0.977 
0 - -







3.37 -34.64 <0.00110.81 
0.99 -1.47 0.0081.21 
The following presenting clinical features were associated with a diagnosis of PCP on bivariate 
(unadjusted) analyses: Younger age, increased respiratory rate amongst children aged < 6 
months, child newly diagnosed with HIV, decreased arterial percentage haemoglobin oxygen 
saturation (Sa02, room air, at presentation, cyanosis, male gender, and increased serum LDH. 
The following were associated with pneumonia's other than PCP: Child on CTX prophylaxis, 
prior hospital admission, and history of vomiting and diarrhoea at presentation. 
PCP was closely associated with increased disease severity as reflected by ICU admissions and 
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3.4 Multivariate analysis and 6nal mo~el characteristics 
Multiple logistic regression was performed, and the following model was selected with the best 
statistical fit (Table 3). This model included the results of 116 children (12 with PCP and 104 
without PCP); the remaining participants were not included due to missing observations not 
recorded during data collection (complete-subjects method of logistic regression). 
The following emerged as independent predictors of PCP: Respiratory rate> 59 breaths/minute, 
age < 6 months, Sa02::S 92, and absence ofhistory ofvomiting at presentation. Other variables 
that were significant on bivariate analyses fell out of the adjusted model. 
Table 3 Final multivariate model of indicators of PCP 
Clinical variable Adjusted odds 
ratio 
95% confidence 
interval (95 % CI) 
p-value 
Respiratory rate >59 breaths/min 
Age < 6 months 
Absence of history of vomiting 





1.5 - 53.2 
2.4 - 99.8 
1.9- 68.0 





Continuous variables in the final model were categorised, with cut-off values chosen in order to 
be easily clinically applicable, and that maximised differences in the outcome, Le. PCP. Box 
plots of these variables stratified by PCP are shown in Appendix 1. Children with an Sa02 of 
:592 would be considered as having significant respiratory compromise. Children aged < 6 
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confounding effect of age on respiratory rate would be "adjusted for" by the multivariate 
modelling. 
The multivariate model has the following characteristics: Area under the receiver-operating 
characteristic (ROC) curve: 0.92 (a measure of the predictive ability of the model). Aikaike's 
Information criteria (AlC): 54.86 (used to compare models that are not nested). 
There was no interaction amongst the variables, as all interaction terms were non·significant. 
Model checking: The form of the linear predictor and the link function were adequate. There 
were no strongly influential or outlying observations (Appendix 2). 
Table 4 shows the findings of the bivariate associations of the variables included in the final 
model with PCP, with categorization of the continuous variables. CTX prophylaxis is also 
included for comparison, as this variable was included in a different multivariate model as 
discussed in section 3.7. Sensitivity and specificity (including confidence intervals) with respect 
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Table 4 	 Bivariate analyses of categorised variables that were independently 
associated with PCP 
Clinical variable PCP Without Odds ratio p-value Sensitivity Specificity 
n (%) PCP (95% CI) (95% CI) (95% CI) 
n (%) 
Respiratory > 59 11 (85) 46 (34) 10.5 0.003 0.85 0.66 
Rate ~59 2 (15) 88 (66) (2.2-4904) (0.55-0.98) (0.57-0.73) 
(breaths/min) 
Age < 6 months 13 (87) 44 (32) 13.5 0.001 0.87 0.68 
2: 6 months 2(13) 92 (68) (2.9-62.8) (0.60-0.98) (0.59-0.75) 
History of Yes 2 (13) 64 (49) 0.2 0.019 0.87 0049 
vomiting No 13 (87) 67 (51) (0.03-0.7) (0.60-0.98) (0040-0.58) 
Sa02 (%) > 92 7 (50) 73 (66) 1.9 0.253 0.50 0.66 
:s 92 7 (50) 38 (34) (0.7-5.8) (0.23-0.77) (0.56-0.75) 
CTX Yes 1 (7) 58 (43) 11.7 0.019 0.93 0046 
prophylaxis No 14 (93) 78 (57) (1.5-91.5) (0.68-0.99) (0.37-0.54) 
Eighty-five percent of children with PCP had a respiratory rate of> 59 breaths per minute, and 
87% of children with PCP were under 6 months of age. Eighty-seven percent of children with 
PCP had no history of vomiting at presentation, and 93% of children who developed PCP were 
not taking CTX prophylaxis. 
Absence of CTX prophylaxis had the highest individual sensitivity for the diagnosis of PCP of 
0.93 (95% CI 0.68 - 0.99), but a low specificity of 0046 (95% CI 0.37 - 0.54). Age < 6 months 
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The weakest of the four variables associated with PCP in the multivariate model was Sa02. 
There was a significant association with PCP on bivariate analysis with SaCh as a continuous 
variable (p=0.032, table 2), and in the final model when categorised (table 3). Addition of this 
variable to the other three variables in the multivariate model also strongly improved model fit 
(likelihood ratio test p-value = 0.007). Categorisation of continuous variables may however 
result in reduced significance of associations, as was evident on bivariate analysis when Sa02 
was categorised (p=0.253, table 4). 
3.5 Measures of diagnostic accuracy of the final predictive model 
Two methods of calculating measures of diagnostic accuracy of combinations of the best 
predictive variables were employed, as discussed in section 1.7. Firstly, table 5 indicates the 
sensitivities, specificities, positive predictive values (pPV), negative predictive values (NPV), 
and likelihood ratio's (LR's) for positive and negative tests according to the number ofclinical 
indicators present (of the final four clinical indicators selected). The calculation of these 
measures assumes that the clinical test has a dichotomous outcome i.e. positive or negative with 
respect to PCP. The third row of the table will for example, indicate the values when the 
presence of any two or more indicators are used to assign the child as having PCP. If none, or 
anyone of the indicators were present, the child would be assigned as not having PCP. 
Each clinical variable has been assigned an equal weighting. Mathematical methods which are 
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classification and regression trees (CART) analysis (Wasson 1985, Mayer 2004) are, due to their 
complexity, beyond the scope of this analysis. 
Table 5 	 Sensitivity and specificity of diagnosing PCP according to the number of the 












LR +ve test 
(95% CI) 









Any 1 1.00 0.08 0.11 1.00 1.1 0 
(0.74- 1.00) (0.03- 0.14) (0.06-0.19) (0.63-1.00) (1.0-1.1) 
Any 2 1.00 0.49 0.18 1.00 2.0 0 
(0.74-1.00) (0.39- 0.59) (0.10-0.30) (0.93-1.00) (1.6- 2.4) 
Any 3 0.75 0.90 0.47 0.97 7.8 0.3 
(0.43- 0.95) (0.83- 0.95) (0.24-0.71) (0.91-0.99) (4.0-15.2) (0.1- 0.7) 
I 
All 4 0.33 0.99 0.80 0.93 34.8 0.7 
(0.10-0.65) (0.95-1.00) (0.28-0.99) (0.86-0.97) (4.3-279.4) (0.5-1.0) 
I 
In order to help guide the choice of the most appropriate cut-off point to use to delineate normal 
or abnormal results for a test with multiple outcomes, the RO~ curve, where, sensitivity is plotted 
against 1-specificity for all combinations of test results, is used. The part of the curve closest to 
the top left hand corner maximizes sensitivity and specificity. Figure 1 shows the ROC curve of 
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Figure 1: Receiver-operating characteristic curve for final predictive model, showing 
points according to the number of clinical indicators present 











0.00 0.25 0.50 
1 - Specificity 
Tables six and seven are two-by-two tables showing the diagnostic ability of the clinical model 

when using two potential cut-off values for a positive test for PCP: 

i) two or more indicators diagnosing PCP (table 6). 
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Table 6 	 Diagnostic ability of the final model using a cut-off value of any two or more 
indicators diagnosing PCP. 
PCP confirmed by IF/staining (n) 
PCP No PCP Total 








Total 12 104 116 
Using this cut-off value, sensitivity is 1.00 (95% CI 0.74 -1.00), with all children with PCP 
being correctly classified as having PCP. The specificity of 0.49 (95% CI 0.39 - 0.59) is 
however low, with 51 of 104 children without PCP being correctly classified as not having PCP. 
Assuming a prevalence of PCP as measured in the study, the probability of having PCP with a 
positive test result (PPV) is low (0.18 (95% CI 0.10 - 0.30), with 53 of 65 children classified as 
positive by the test not having PCP. 
Table 7 	 Diagnostic ability of the final model using a cut-off value of three or more 
indicators diagnosing PCP 
PCP confirmed by IF/staining (n) 
PCP No PCP Total 
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A cut-off value of three or more indicators diagnosing PCP improves specificity to 0.90 (95% CI 
0.83 0.95), with 94 of 104 children without PCP being correctly classified as not having PCP. 
Sensitivity, 0.75 (95% CI 0.43 - 0.95) is however decreased, with three of 12 children with PCP 
being misclassified as negative. PPV (0.47 (95% CI 0.24 - 0.71) is modestly improved, but is 
still low. NPV values for both cut-points are >0.90. 
Confidence interval's surrounding the estimates of test diagnostic accuracy are wide, as 
discussed in section 4.5. 
3.6 Interval likelihood ratio's of the final predictive model 
Table 8 indicates the iLR's for each level of test outcome, i.e. according to the number ofclinical 
indicators present in a child. This table differs from Table 5 in that the diagnostic test has 
mUltiple outcomes instead of a simple dichotomous outcome, which has the advantage that 
categories of test outcomes are not collapsed, resulting in greater test information being 
available. 
Post-test probabilities of PCP vary according to the pre-test probability of PCP and the iLR of 
each level of test outcome. The pre-test probability of the disorder of interest for a clinical rule, 
is the prevalence of the disorder in the population at risk (HIV -infected children hospitalised 
with pneumonia), which was 10% in this sample. The proportion of PCP in HIV -infected 
children in Mrica has been reported to be as high as 49% amongst children with severe 
pneumonia (as discussed in sections 1.1 and 4.1). Post-test probabilities of PCP have been 
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the 95% CI of the proportion of PCP in the sample (6%) has also been included as a pre-test 
probability. 
Table 8 	 Interval likelihood ratios and post-test probabilities of PCP with varying pre­







Post test probabilities, % (95%CI) of PCP according to 
pre-test probabilities of PCP 
6% 10% 49% 
(severe pneumonia) 
0 0 0 0 0 
Any 1 0 0 0 0 
Any 2 0.6 (0.2- 1.7) 4 (1-10) 7 (2-16) 38 (18-62) 
Any 3 5.0 (2.0- 12.5) 24 (11-44) 36 (18-58) 83 (66-92) 
All 4 36.0 (4.4- 96.5) 70 (22-86) 80 (33-97) 97 (81-100) 
...
Three pre-test probabilities ofPCP have been used, VIZ. the samples' proportion of PCP pomt estimate (10%) 

and lower 95% CI limit (6%), and the maximum reported proportion of PCP amongst HIY -infected 

children hospitalised with pneumonia (49%). 

The iLR when none, or anyone clinical indicator is present is zero, with resulting post-test 
probabilities of PCP being zero, irrespective of the pre-test probability. When all four indicators 
are present, the iLR is 36.0 (95% CI 4.4-96.5), with post-test probabilities of PCP that are 
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test probability of PCP increases, with a post-test probability of PCP of 97% (95% CI 81% ­
100%) when the pre-test probability is 49% .. 
Table 9 shows illustrative implications of a clinical decision rule (CDR), based on the confidence 
interval limits of the post-test probabilities of PCP (for all pre-test probabilities) from table 8. A 
threshold post -test probability of PCP of 2:: 10% has been used to indicate initiation of specific 
anti-pneumocystis treatment (as discussed further in section 4.4.2). 
Table 9 	 Illustrative implications of a clinical decision rule for PCP according to the 
number of clinical indicators present 
I Number of 
indicators presentI 
Children per row 
category (%) 
Post-test probabilities of 
PCP, % (95% CI limits) 
Management action 
. Zero or one 43.9 Low,O (-) Withhold specific treatment 
Two 39.7 Intermediate, 4-38 (1-62) Indeterminate (Further 
investigation if available) 
Three or four 16.4 High, 24-97 (11-100) Initiate specific treatment 
Zero or one clinical indicator in a child is associated with a post-test probability of PCP of 
< 10%, indicating withholding of specific anti-pneumocystis treatment. Three or four indicators 
being present has a post-test 95% CI lower limit of>10%, indicating initiation of specific 
treatment. Two indicators are associated with post-test probability 95% CI limits on both sides of 
the threshold probability; therefore management is indeterminate. Table 10 illustrates the 
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Table 10 Implicatioos of the CDR io the study sample 
PCP (0=12) 
0(%) 




Correctly managed 9 (75.0) 51 (49.0) 60 (51.7) 
i Incorrectly managed 0(0.0) 10 (9.6) 10 (8.6) 
Indeterminate (two indicators) 3 (25.0) 43 (41.3) 46 (39.7) 
Seventy-five percent of children with PCP would correctly receive specific anti-pneumocystis 
treatment, and 0% would not receive treatment, however 25% would fall in the indeterminate 
group. Only 9.6% of children without PCP would unnecessarily receive anti-pneumocystis 
treatment, and 49% of children without PCP would correctly not receive specific treatment. 
The iLR's of a diagnostic test are useful, if they alter the pre-test probability to cross the 
threshold value in which treatment (or further investigation) is either initiated or withheld. Table 
11 shows prevalence scenarios in which use of this CDR would produce changes in management 
decisions in children, in areas where definitive diagnosis of PCP is unavailable. Pre-test 
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Table 11 	 Prevalence scenarios that would produce changes in management decision 
with use of the CDR 
No. of Pre-test Post-test Specific Specific Indicator of CDR 
indicators probability probabilities of treatment treatment changing 
present ofPCP(%) PCP, % (95% started started using management 
CI limits) without CDR CDR (treatment 
(Yes/No) (Yes/No) threshold crossed) 
zero or 6< 10 0 N N 
one 2:10 0 Y N ** 
three or 6 < 10 24 - 80 (11-97) N Y ** 
four 2:10 36 - 97 (18-100) Y Y 
Use of the CDR would produce a change in management to not initiate PCP treatment when zero 
or one indicator is present, when the pre-test probability of PCP is 2:1 0%. A change in 
management to start treatment is produced when three or four indicators are present, when the 
pre-test probability is between 6 and 10%. 
3.7 Other models evaluated 
1. 	 A multivariate model with the next best statistical fit (model 2), included the variable 
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Table 13 Characteristics of the best predictive model and model 2 
AlC Area under ROC curve 
Best predictive model 54.86 0.92 
Model 2 58.80 0.91 
The AIC of model 2 is higher, indicating poorer data fit than the first model, and the area under 
the ROC curve is marginally lower. The first model that included Sa02 is therefore statistically 
the better model. 
Table 14 Further models evaluated 
Clinical variables included in model Comment 
RR>59 
age <6 months 
Sa02~92 
absence of vomiting 
no CTX prophylaxis 
No CTX prophylaxis was not significant in this 
model (p=0.214), and did not improve the 
goodness':'of-fit when added to the other four 
variables (LR test chi-square p-value = 0.168). 
4 RR>59 
age < 6 months 
Sa02~92 
no CTX prophylaxis 
No CTX prophylaxis was also non-significant 
in this model (p=0.224) and did not improve the 
goodness-of-fit when added to the other three 
variables (LR test chi-square p-value = 0.174). 
5 Specifically including serum LDH with 
combinations of the other variables, as 
increased serum LDH was strongly 
associated with PCP on univariate 
analysis. 
LDH was however not significant on 
multivariate analysis (p=0.151) and did not 
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4 DISCUSSION 
4.1 Patient characteristics 
One hundred and fifty one children were included in the sample, which compares favourably in 
size with other investigators who have compared the presentation of HIV-infected children with 
pneumonia (Ansari 2003: 35 participants, Ruffini 2002: 105 participants, Graham 2000: 150 
participants). Only Madhi and colleagues (2002) had a larger sample size consisting of 231 
episodes of pneumonia (101 episodes of PCP) amongst 185 children. 
The proportion of PCP in the sample (9.9%) was similar to the Malawian sample of 10.6% 
(Graham 2000), but lower than was found in the two studies from Johannesburg (43.7% and 
48.6%, Ruffini 2002, Madhi 2002). Investigat rs however used differing sample selection 
criteria, diagnostic techniques, and diagnostic criteria for PCP. It is therefore difficult to 
interpret if these varying measurements reflect true geographic variation in the burden of PCP, or 
are due to the differing study methods used. The following may have influenced the lower 
proportion of PCP found in this study: 
i) 	 Patient selection was different in the two studies from Johannesburg, as children with 
only severe pneumonia as defined by the World Health Organization clinical criteria 
(WHO 1994) were included. Children with PCP have pneumonia'S of increased 
severity than children with pneumonia of other aetiologies, as reflected by increased 
rates of ICU admission and in-hospital death (table 2). The incidence of PCP in these 
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ii) 	 This study diagnosed PCP with visualisation of five or more cysts on microscopy, 
while the studies from Johannesburg diagnosed PCP with visualisation of two or 
more cysts. This would further contribute to the higher proportions of PCP reported 
there. 
iii) 	 Due to resource constraints, it was not possible in the Cape Town study to perform 
post-mortem examinations to detect PCP in children who died, as was done in the 
Johannesburg studies. The sensitivity of IS samples for PCP is 65% compared with 
post-mortem histology, therefore possible cases of PCP in this sample may not have 
been diagnosed. 
4.2 	 Clinical indicators of P.jiroveci infection 
Four clinical features were found to be independently associated with PCP in the sample: 
• Age at presentation 
Children with PCP were significantly younger than those without PCP. This has similarly been 
found by three other investigators (Ansari 2003, Graham 2000, Madhi 2002). 
• Respiratory Rate 
Children aged < 6 months with PCP had significantly higher respiratory rates than those without 
PCP. Madhi and colleagues (2002) found a similar association amongst children aged < 1 year. 
Graham and colleagues (2000) found no association between respiratory rate and PCP, however 
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analysis, respiratory rates of >59 breaths/min would only have significance in identification of 
children with PCP if they were also below 6 months of age. 
• Absence of history of vomiting at presentation 
This symptom was strongly associated with PCP in both bivariate and multivariate analyses. 
Other researchers have not measured history of vomiting at presentation. Vomiting may be a 
feature of lower respiratory tract infections where hyperinflation predominates, resulting in a 
flattened diaphragm and a compressed stomach, whereas hyperinflation is not usually associated 
with PCP. Another possible reason may be that children who have had vomiting are more likely 
to have aspiration pneumonia as opposed to PCP. The association may also be due to chance, 
considering that a large number of clinical variables were compared with the presentation of PCP 
from the database. Further research however needs to be performed in this area. 
• Median arterial percentage haemoglobin oxygen saturation in room air 
As in this study, Graham and colleagues found a reduced median Sa02 amongst children with 
PCP (p = 0.003, Graham 2000). Children with PCP therefore have greater respiratory 
compromise than children with pneumonia of other aetiologies. A cut off value of <92% is 
clinically meaningful to use if an oximeter is available, and suggests increased repiratory 
compromise. 
4.3 Multiple logistic regression results 
Many of the clinical variables that were significant on bivariate analyses were non-significant on 
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four variables, as further increases in the number of variables did not improve prediction of the 
outcome, and would increase the difficulty of clinical use. 
The final model had a lower AlC and a higher area under the ROC curve than model 2 (which 
included absence of CTX prophylaxis), indicating that it was more effective in predicting 
outcome. The AlC is a measure of comparing model fit in non-nested models. The model with 
the lower AlC generally fits the data best, and it is used to help select the most appropriate 
predictor variables (Collet 1994). The ROC curve is a plot of sensitivity vs. i-specificity for a 
specific diagnostic test (Altman 1991). A perfectly predictive model has an area under the curve 
of 1.0, with lower values indicating poorer predictive power, and an area of 0.50 indicating no 
discriminatory value. 
Absence of CTX prophylaxis was significantly associated, and sensitive in the diagnosis of PCP 
in bivariate analyses, however it failed to reach significance at the 5% level in the multivariate 
analyses. As discussed in section 1.1, numerous studies have demonstrated the benefit of CTX 
in preventing PCP (Thea 1996, Rigaud 1994, Duong 1999, Chokephaibulkit 1999, Ruffini 2002, 
Chintu 2004), and CTX is currently "recommended for primary prophylaxis against PCP in all 
infants born to HIV-infected women in industrialised and resource-poor countries, from six 
weeks of age and continuing until HIV-infection status is negative. In HIV-infected children 
after infancy, CTX is recommended if CD4 counts are less than 15% of total lymphocyte count." 
(Chintu 2004). Concerns have however been expressed that CTX prophylaxis may lead to 
bacterial resistance to antibiotics, resistance of malaria parasites to sulfadoxine­
pyrimethanamine, and that it may be ineffective in areas that demonstrate high levels of bacterial 
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a significant reduction in PCP among children considered to have received adequate prophylaxis, 
and Gill and colleagues (2004) consider that a policy of mass CTX prophylaxis may be 
counterproductive in certain circumstances. 
This analysis has failed to show an independent protective effect of CTX prohylaxis in relation 
to PCP. The validity of this observation is however questionable, as the study was not 
specifically designed to measure the drugs' effect, subjects were non-randomised, use of CTX 
was measured by questioning on retrospective use, and adherence could not be validated. 
4.4 Measures of diagnostic accuracy and their clinical relevance 
4.4.1 Sensitivity and specificity 
The sensitivity of a diagnostic test is the proportion of subjects with the target disorder in whom 
the test result is positive. Specificity is the proportion of subjects without the target disorder in 
whom the result is negative. These measures are useful to evaluate diagnostic tests in groups of 
subjects, but less helpful in applying results to individual patients. In a diagnostic test with 
multiple outcomes, a cut-off value needs to be chosen to divide test results into normal and 
abnormal. There is usually a trade-off involved between sensitivity and specificity when 
selecting a cut-off level, which is shown in the ROC curve of the final model (Figure 1). The 
part of the curve closest to the top left-hand corner indicates maximum sensitivity and 
specificity. 
The prognosis of an HIV-infected child with untreated PCP is extremely poor, so children with 
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maximised. A cut-off value of any three or more indicators producing a positive test has an 
unacceptably low sensitivity of 0.75 (95% CI 0.43-0.95). Alternatively, using a cut-off value of 
any two or more indicators producing a positive test has a higher sensitivity of 1.00 (95%CI 
0.74-1.00), but the specificity of 0.49 (95%CI 0.39 - 0.59) is poor. A PPV of 0.18 (using this 
studies' prevalence ofPCP) would also result in an acceptably high proportion ofchildren who 
would be classified as positive by the test who do not have PCP (82%). These children would 
receive specific treatment unnecessarily, with its resultant potential for adverse effects. 
4.4.2 Likelihood ratio's and post-test probabilities of PCP 
LR's are alternate measures ofdiagnostic accuracy that indicate the magnitude that a diagnostic 
test (or rule) will raise or lower the pre-test probability of the target disorder. The LR can be 
calculated for each level of test outcome (the iLR), and diagnostic tests may therefore have more 
then simply positive or negative results (Mayer 2004). An iLR of 1 indicates no alteration in the 
pre-test to post-test probability of the target disorder. The higher the iLR is above 1, the greater 
the increase in probability that the disorder is present. Alternately, the lower the iLR is below 1, 
the greater the decrease in probability of the disorder. 
In order to attach meaning to this diagnostic measure, the following categories are used as a 
guide to the strength of the usefulness of an iLR: iLR> 10 or < 0.1: conclusive change in pre­
test to post-test probability; iLR 5-10 or 0.1- 0.2: moderate change in probability; iLR 2-5 or 0.2 
- 0.5: small change in probability (may be important); iLR 1-2 or 0.5-1: small, mostly 
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The iLR is used to calculate the post-test probability of the condition from the pre-test 
probability. Differing pre-test probabilities will produce differing post-test probabilities for the 
fixed iLR of each outcome. For an iLR to be useful it should alter the pre-test probability to cross 
a threshold value, in which treatment (or further investigation) is either initiated or withheld. 
Published threshold values based on clinical suspicion, for the initiation of specific treatment for 
suspected PCP in HIV-infected children with pneumonia, have not as yet been produced, and 
attending physicians working in areas where definitive diagnosis is not available must use their 
own discretion, considering the risks and benefits of treatment, when making management 
decisions. A suggested threshold value, however, is to start specific treatment if the probability 
of PCP is considered to be 2:10% (Zar HJ,personal interview, September 2004), as used in the 
illustrative example for the CDR (tables 9 and 10). The nature ofthe Cl's ofthe post-test 
probabilities of PCP (for all pre-test probabilities), would however allow threshold values 
ranging from 1 % - 11% without the structure of the CDR being altered. 
Use of the CDR in this sample would result in no children with PCP being incorrectly excluded 
from receiving specific treatment, and fewer than 10% of children without PCP would 
unnecessarily receive specific treatment. In order to confidently place children in the category of 
not receiving specific treatment, the upper limit of the confidence interval of the post-test 
probability of PCP also needs to be below the treatment threshold. The upper confidence limit of 
, . 
the iLR and post-test probability of zero cannot however be calculated, and PCP can therefore 
not be confidently excluded at the population level, when zero or one indicator is present in a 
child. The results of this analysis can therefore not be used to inform on clinical management 
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The usefulness of a diagnostic test is also influenced by the proportion of patients suspected of 
having the target disorder, whose test results have high or low iLR's which move patients across 
a treatment threshold (Jaeschke 1994). The proportion of children in this sample with categories 
ofiLR's that potentially produce clinically relevant changes in the probability of PCP is 60.3% 
(zero, anyone, three, or four indicators present, table 9). 39.7% of children in the sample 
however fell in the indeterminate category of the CDR (children with two indicators present). 
The category contained 3(25%) of those who had PCP. This category of children may however 
be suitable for further diagnostic investigation for PCP in areas that have access to diagnostic 
equipment, but due to geographical distance or resource constraints, are able to investigate only a 
limited number of children. Laboratory investigations revealed PCP in 3 (6.5%) of 46 children 
in this category; this is nevertheless an important diagnostic yield due to the serious nature of the 
disease. 
It is interesting to note that in the clinical management of children in the sample, all except one 
child received empirical broad-spectrum antibiotic treatment prior to laboratory diagnostic . 
results becoming available. A low proportion (17%) of the sample however received anti­
pneumocystis treatment empirically, and only 6 of 15 children later confirmed to have PCP 
received specific treatment empirically. The proportion of the sample started on anti­
pneumocystis treatment empirically may be expected to be higher with a pre-test probability of 
PCP (9.9%) which approximates the suggested treatment threshold (10%). A clinical prediction 
method for PCP had however not yet been investigated at the time of the study, and children 
were hospitalised in tertiary centres, where clinicians could generally expect diagnostic 
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cautious about starting specific therapy. The burden of paediatric PCP in Africa had also been 
poorly described at that time, and may have been expected to be lower than it actually was. 
4.5 	 Strengths and weaknesses of the tinal predictive model 
In summary, the strengths of the final predictive statistical model are as follows: 
1. 	 Four clinical indicators have been identified that are independently associated with PCP 
in HIV -infected children hospitalised with pneumonia. 
2. 	 Ease of clinical use, as all indicators are easily measured. 
3. 	 The post-test probability of PCP, based on the number of these indicators in an individual 
child, can be roughly estimated. 
The weaknesses of the final model are: 
1. 	 Confidence intervals (CPs) for the estimates ofdiagnostic accuracy (iLR's, post-test 
probabilities, sensitivity and specificity) of the model are large, due to: 
i) Small numbers of children with PCP in the sample (type II error). Theoretical 
analyses have shown that the sample should contain at least five subjects (Wasson 
1985), but preferably twenty (Mayer 2004) with the outcome of interest, for each 
predictive finding in the clinical rule. This rule has four predictive clinical 
findings, therefore the sample should have at least 20, but preferably 80 cases of 
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ii) 	 Missing observations amongst certain of the clinical indicators resulted in 35 
children (three with PCP) being excluded from the final multivariate model, 
which further contributed to reduced statistical power of the analysis. 
The imprecision of the effect measures make it difficult to base firm conclusions 
or consequent clinical recommendations upon these results. 
2. 	 The biological explanation of history of vomiting in relation to PCP is as yet unsure. 
4.6 Final predictive model conclusions 
1. 	 This predictive model provides preliminary evidence in the clinical prediction of 
PCP in HIV-infected children hospitalised with pneumonia, and can estimate the 
posterior probability of PCP based upon four easily measured clinical criteria. 
2. 	 It is most useful to use the iLR of categories of test outcome to calculate the post­
test probability of PCP. Using a single cut-off to demarcate a dichotomous 
positive or negative test outcome produces a loss of useful information. 
3. 	 An illustrative CDR has been derived that divides children into three categories to 
either receive or to not receive specific treatment for PCP, and children that 
require further diagnostic investigation (where available). 
4. 	 This CDR can however not be recommended for clinical use at this stage, as it 
cannot confidently be estimated that children with zero or one clinical indicator 
will not have PCP at the population level. The imprecision of the measures of test 
accuracy also make it difficult to base firm conclusions on the results. The CDR 
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according to McGinn and colleagues (2000), that has been derived but not 
validated. It would need to be re-evaluated in further adequately designed studies 
with larger sample sizes, in order to quantify measures of diagnostic accuracy 
with greater precision, before it can be suggested to aid in clinical decision 
making, if appropriate. 
4.7 Strengths of Study 
• 	 "The optimal design for assessing the accuracy of a diagnostic test is considered to be a 
prospective blind comparison of the test and the reference test in a consecutive series of 
patients from a relevant clinical population. A relevant clinical population is a group of 
patients covering the spectrum of disease that is likely to be encountered in the current or 
future use of the test" (Lijmer 1999). This study was a prospective study, and enrolment 
of consecutive patients is likely to have included subjects with a clinically meaningful 
spectrum of disease. (The study population however consisted of children admitted to 
secondary and tertiary hospitals, therefore the results of the study cannot be generalised 
to include children presenting with pneumonia at primary care levels.) 
• 	 Interpretation of the reference test results by the laboratory staff was done without 
knowledge of the results of the clinical diagnostic test under study, i.e. it was a blind 
(masked) study. 
• 	 Verification bias did not occur, Le. the decision to perform the reference test was not 
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4.8 	 Limitations of study 
This study has the following limitations: 
• 	 Admitting doctors did not have a standardised assessment protocol or data-capture form at 
admission of each child. The number of admitting doctors was not recorded, and admitting 
doctors were not necessarily briefed on aspects of the study and the need for complete data 
capture. A person other than the doctor who first examined the child captured the clinical 
data on the study data capture form from the admission notes. Standard definitions of all 
potential clinical predictive findings were also not detailed prior to the study. The quality 
of clinical data is therefore questionable. Inter-observer variation in the assessment of the 
clinical variables is cosequently likely, which would produce a non-differential 
misclassification bias of index variables, biasing study estimates towards the null, i.e. 
produce an under-estimate of accuracy of the test (Wasson 1985, Katzenellenbogen 1997). 
Inter-observer agreement of the presenting clinical observations between two or more 
clinicians was not measured, therefore the magnitude of the bias cannot be quantified. 
• 	 A non-differential misclassification bias of the outcome (PCP) in the sample is possible, 
as due to resource constraints of the original study, post-mortem lung biopsy and BAL 
examination of all children could not be performed. Cases of PCP may therefore have 
been misdiagnosed, as IS samples have a lower sensitivity and specificity than BAL in . 












Chapter 4: Discussion 
• The post-hoc selection of the cut-off points for the categorisation of the continuous 
variables in the predictive model may be a source of type I statistical error, and bias 
toward an over-estimate of accuracy of the diagnostic test (Mayer 2004). 
• Provision was not made during data collection for multiple infective pathogens. Prior to 
the study in 1998, there had been case reports and series of viral and bacterial co­
infections with P. jiroveci infection. Prospective evaluations of the frequency of this 
occurrence have subsequently found co-infections with PCP to be relatively common 
(Madhi 2002, Chintu 2002). 
• The number and clinical details of eligible children excluded from the study were not 
recorded. Children excluded from the study may differ systematically from the study 
participants in terms of the index clinical variables or the outcome, potentially biasing 
outcome measures in either direction. 
• The rates of misclassification of the test have not been estimated for a new theoretical 
population using statistical cross-validation techniques, such as the split-sample, jacknife 
or bootstrap methods (Wasson 1985). 
• Many clinical features were compared in children with and without PCP, and statistical 
power of this study was low due to the small number of children with the outcome. The 
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4.9 Reporting of study 
The reference test, the clinical diagnostic test, arid the study population have been 
described with sufficient detail to "allow for replication, validation and generalisation of 
the study," as recommended by Lijmer and colleagues (1999). Descriptions of diagnostic 
tests are considered sufficient if clear definitions of positive and negative test results are 
mentioned. Description of the study population is considered sufficient if two of the 
following characteristics are described: age of participants, female to male ratio, or 
distribution of symptoms the former two were described in this study. 
This report also includes 22 of 25 criteria recommended for the reporting of diagnostic 
accuracy studies, according to the Standards for Reporting of Diagnostic Accuracy 
(STARD) steering group (Bossuyt 2003). The items not included were: Report estimates 
of variability of diagnostic accuracy between readers, centres or participant subgroups if 
done (item 23); and report estimates of test reproducibility if done (item 24). Neither 
were measured in the original study. Item 10 (describe the number, training and expertise 
of the persons executing and reading the index tests and the reference standard) was 
partially fulfilled (the number of doctors admitting the sample children was not 
measured). 
4.10 	 Future studies 
Further studies are needed in order to attempt to define a valid CDR. These studies 
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• Sample size and power: The sample should contain a minimum of 20, but 
preferably 80 cases of PCP in order to increase precision of the estimates of 
diagnostic accuracy, as discussed previously. Assuming a 10% proportion of PCP 
amongst HIV-infected children hospitalised with pneumonia, the total sample size 
required would therefore be 200 800 children. At the rate of enrolment of 
children at the four hospitals that were used in the original study, it would 
however take over five years to achieve a sample size of 800. 
• Explicit definitions of all potential clinical predictive findings should be stated, 
with standardised and complete data capture methods used by the doctors on 
hospital admission of the child. Inter-observer agreement should ideally be 
measured, and only those observations with a high inter-observer reliability (kappa 
statistic) should form part of the final rule. 
• Post-mortem lung biopsies should be performed on children who die during the 
study, as this is the most accurate method for identifying the aetiological agent 
responsible for the pneumonia (Chintu 2002). These results should be correlated 
with ante-mortem diagnoses. 
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• 	 A mathematical model to create a rule that incorporates varying weights for each of 
the clinical predictors may be used. 
• 	 Statistical cross-validation techniques may be used to validate the rule in the study 
population from which the rule was derived. 
The CDR derived in this analysis may also be evaluated in a different setting and 
population, with prospective measuring of the rate of misclassification. 
Future research should also aim to produce explicit treatment threshold values for the 
initiation of anti-pneumocystis treatment in HIV-infected children based on clinical 
criteria, for use in areas where laboratory diagnostic measures for PCP are limited. 
The relationship between vomiting and PCP should be evaluated in further epidemiologic 











Chapter 5: Conclusion 
5 CONCLUSION 
This study has shown that four presenting clinical features are independent indicators of the risk 
of PCP amongst HIV-positive children hospitalised with pneumonia in South Africa, namely 
respiratory rate> 59 breaths/per minute; age < 6 months; SaOz:S 92; and absence ofhistory of 
vomiting at presentation. 
A multivariate model has been described that estimates interval likelihood ratio's and post-test 
probabilities of PCP for differing numbers of these indicators. There is a low probability of PCP 
with zero or one clinical indicator in a child, and increasing probabilities with the presence of 
any three or all four of the indicators. The derived CDR may have use in assigning children to 
treatment categories, and in identifying children that require further diagnostic investigation 
should this be available for a limited number of children. 
This analysis provides preliminary evidence in the clinical prediction of PCP in HIV-infected 
children with pneumonia. The CDR is however unable to conclusively identify children at the 
popUlation level that do not require specific anti-pneumocystis treatment. The important 
measures of test diagnostic accuracy are also imprecise, and design-related biases may have 
influenced the results. Conclusions or clinical recommendations can therefore not be based on 
the results at this stage. Further studies that are specifically designed to validate clinical 
predictors of PCP in HIV-infected children should be undertaken, in order to quantify measures 
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APPENDIX 1: Box plots of continuous variables in the final model indicating 
categorisation cut-off values. 
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APPENDIX 2: Model-checking procedures for the final model. 
Four aspects of the final statistical model were checked, namely: 
1. Assessment of the form of the linear predictor. 
2. The appropriateness of the link function. 
3. Detection and description of outlying observations. 
4. Detection and description of influential observations. 
1. Assessment of the form of the linear predictor. 
Plots of standardised deviance and Pearson residuals were plotted against the observation 
number (index plots, Figures 6 and 7). A systematic pattern in these plots would indicate 
that the model is incorrect. 
Standardised deviance residuals were plotted against the linear predictor (Figure 8). Two 
distribution curves are typically seen for binary data, which would indicate adequacy of 
the linear predictor. 
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No systematic pattern is detectable in either of these plots, indicating that the linear component 
of the model is adequate. 
Figure 8: Plot of standardised deviance residuals vs. linear predictor 
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2. 	 The LOGIT transformation is always appropriate for a binary response as used in this 
analysis, and therefore does not need checking. 
3. 	 Outlying observations. 
Figures 6 and 7 are also used to detect outlying observations with residuals >121. 
Two subjects are identified as potential outliers, namely study-numbers 19 and 223, however 

their standardised residuals are < 121 indicating that they are weak outliers. 

Description of these subjects: 

Study-number 19: Did not have PCP despite having a respiratory rate of 50, age of 3 months, 

Sa02 of 90%, and no history of vomiting. 

Study-number 223: Did not have PCP despite having a respiratory rate of 18, age of 3 months, 

Sa02 of 90%, and no history of vomiting. 

4. 	 In order to identify observations with high leverage (influential observations), a plot of 
the leverage statistic (hI) is drawn against the observation number (Figure 9). 













Figure 9: Plot of leverage statistic (h~ vs. study-number 
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No subjects with high leverage are observed. 
Model Checking Conclusions: 
1. The form of the linear predictor is adequate. 
2. The link function is adequate. 
3. There are no strong outlying observations. 
























Total n1 n2 
Matrix when obtaining multilevel test results 
The point estimate of the interval likelihood ratio of level 2 is given by the equation: 
LR2 = 	.Pl... = E I(A + E + G + C) = E I ni 
p2 F I(B + F + H + D) F I n2 
Where PI =proportion of diseased patients with a given test result 
pz = proportion of non-diseased patients with the same test result 
The 95% confidence interval of the interval likelihood ratio is calculated as follows: 
LR 2 = exp[ln _PI ± 1.96. 1- pI + _1_-..::...P_2] 












APPENDIX 4: Calculation of post-test probabilities using Bayes' theorem 
(Adapted from Buchsbaum 1991, Mayer 2004) 
iLR .P I 

I - PI
P 2 = 
iLR .P I
I + 
I - PI 
Where P1 =pre-test probability of disease 
P2 =post-test probability ofdisease 
iLR =interval likelihood ratio 
Confidence interval limits of the post-test probabilities of disease are calculated using the 
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Pain is an important problem in the care of children with all stages of cancer but especially in the 
'end of life' phase. The World Health Organization (WHO) confirms that palliative care serves to 
affirm life through the active total care of patients whose disease is not responsive to curative 
treatment. Cancer pain management in the child requires an in-depth knowledge of both the generf 
management of children and the manifestations of paediatric pain. It is ethically wrong to allow a 
child to suffer uncontrolled pain. Every child deserves to have adequate and safe pain control. The 
goal of management is to achieve the best quality of life (QOL) for patients and their families during 
illness and bereavement. The child with cancer is usually part of a larger family unit; the needs and 
input of parents, siblings, and extended family members need to be addressed in order to achieve 
optimal relief for the child. 
The assessment and measurement of paediatriC pain requires the understanding of normal 
development and behaviour, recognition of age-appropriate verbal and behavioural manifestations c 
pain, and the knowledge of the tools currently available for the assessment and treatment of 
paediatric pain. 
Drugs for pain and symptom control in children, the dosing guidelines and specific toxic 












SOUTH AFRICAN SITUATION 

In South Africa (SA) there are 9 paediatric oncology units (POU) which treat children with cancer ar 
therefore are involved in the management of cancer pain in children. 
Each POU has its own pain and symptom management regimen and it is unknown whether there i: 
any conformity in the management of pain by the different units in the country. If there is no 
consensus on pain management in children in the RSA, physicians who move from one Province tc 
another, probably manage pain as they were taught in the unit where they previously worked, whiG! 
can lead to continued diversification. 
LITERATURE REVIEW 
Almost all children with cancer will experience pain. It could either be as a direct result of the 
disease, as a side effect of treatment, as the result of invasive clinical procedures, or as an aspect 
psychological distress. In 70% of cases, pain will at some stage become severe. Although the 
means to relieve pain are widely available, in developed and developing countries alike, their use ir 
children has often been very limited. There is a need to address the lack of knowledge of children's 
perception of pain and illness. Non-drug, supportive measures need to be evaluated again, and USE 
in the daily management of pain control. Reasons for inadequate pain control could include 
inappropriate drug doses, and the fears of drug 'addiction' resulting in the fact that the general key 
principles of analgesic drug administration ('by the ladder', 'by the clock', by the child' and 'by the 
mouth') are not followed. 
We need emphasis on a holistic approach. Management of pain should not be in isolation but as pc 












We need to recognize children's psychological, social and spiritual problems and to allay their fear 
and answer their questions with honesty. 
The value of involving family members in treatment and support must be appreciated. 
KEY PRINCIPLES 
The general principles of analgesic administration which is advocated by health professionals are: 

'by the ladder', 'by the clock', 'by the child', and 'by the mouth'. 

The World Health Organization (WHO) initially developed the ladder approach. 

'BY THE LADDER' 

'By the ladder' refers to a three-step approach for selecting progressively stronger drugs 

progressing from paracetamol to codeine to morphine to correspond to the child's pain level which 





Non-opioid analgesic (for example, paracetamol, NSAID) 
+/- Adjuvants (antidepressants, anticonvulsants, steroids) 
Ifpain persists or increases 
STEP 2 
Weak opioids analgesic (for example, codeine) 
+/- Non-opioid analgesic 
+/- Adjuvant drugs 
Ifpain persists or increases 
STEP 3 
Strong opioid analgesic (for example, morphine, diamorphine) 
+/- Non-opioid analgesic 
+/- Adjuvant drugs 
The use the World Health Organization (WHO) ladder of treatment allows for a systemic 














arising from any cause. If pain persists despite using the appropriate drug, recommended 
dose, and dosing schedule, children should receive the next more potent analgesic. 
'BY THE CLOCK' 
'By the clock' refers to the timing for administering analgesic medications. Analgesics should be 
administered on a regular schedule (e.g. every 4 or 6hours, based on the drugs duration of action 
and the severity of the child's pain) not on a pro re nata basis, unless the pain episodes are truly 
intermittent and unpredictable. 
On a pro re nata basis, children must first experience pain before they can obtain pain relief. Childn 
should receive analgesics at regular times, 'by the clock', to provide consistent pain relief and 

prevent breakthrough pain. 

'BY THE CHILD' 

'By the child' refers to the specific needs of the individual child. There is no perfect, universal dose 

that will be appropriate for all children with pain. The goal is to keep the child pain free and to select 

a specific dose, wl"lich will prevent a particular child from experiencing pain before he/she receives 

the next dose. 

'BY THE MOUTH' 

'By the mouth' refers to the route of drug administration. Medication should be administered to 

children by the simplest, least painful and most effective route, usually by mouth. 

COMMUNICATION WITH PARENTS 
Parents want to be actively involved in making decisions about their child's care. They value honest, 
accuracy, clarity and compassion in their providers. 
Parents should be informed about pain relief and they should be aware that pain control plans are 













Optimum palliation requires the establishment of open and ongoing communication among all care 
team members, the child, and the family. 
Every unit should have information leaflets available for the parents, care team members and fami 
involved in the pain management of the individual patient. A general information leaflet about canCE 
pain, the ladder approach, adverse effects of analgesics used and contra indications of the NSAID~ 
are very helpful and valuable to the unit and the parent. Every unit should compose information 
leaflets to suit their circumstances. The leaflet will have to be translated in to all the most frequently 
used languages. See Appendix F as an example of a patient leaflet on morphine. 
ROUTE OF ADMINISTRATION OF PAIN RELIEF 
The preferred route for drug administration is orally. The rectal, subcutaneous or intravenous route 
should be used for patients with persistent vomiting, post operative GIT dysfunction or depressed 
level of consciousness. Disadvantages of difficult routes are the following: pain and discomfort, 
operator experience required, unpredictable absorption, costs and maintenance of the specific roUtf 
Verbal consent should, whenever possible, be obtained from the parents and child when the rectal 
route is used for drugs. The use of syringe pumpsfor subcutaneous or intravenous delivery of 
analgesic agents is well documented. This provides the options of a continuous 24hr infusion 
reaching steady state levels or intermittent bolus of which the pharmacokinetics is less predictable. 
further advantage is the possibility of adding the following drugs with morphine as part of a 

















Routes of administration of analgesics should be discussed with the child and parents. 
LOCAL ANAESTHETIC DRUGS 
Procedure-related pain is a significant problem for many children receiving cytotoxic chemotherapy 
Eutectic mixture of local anaesthetics (EMLA) consists of lignocaine 2,5% plus prilocaine 2,5%. Th 
topical cream (5%) provides effective superficial anaesthesia, and promises to be extremely useful 
for pain relief during percutaneous access procedures in cancer patients. EMLA cream needs at 
least 45min (ideally 60-90min) to work; onset is slower in non-Caucasians, because its absorption i~ 
impeded by melanin in the skin. It constricts capillaries in the skin, causing blanching. The 
constriction resolves 15min after removal of the cream, although the analgesia persists for 1 h. Skin 
irritation may occur if the cream is left on for more than two hours. A study by AW Miser and TS Go 
(1994) showed a statistically significant decrease in pain intensity scores (P< 0.002), recorded by 
both children and investigators, during the use of EMLA cream as compared with placebo. 
Amethocaine gel (Ametop) contains 40mg/g of amethocaine. It is used in the same way as EMLA 
but, unlike EMLA, may dilate capillaries making the siting of cannulae easier. There is adequate 
analgesia after 30min. for venepuncture and after 45min. for venous cannulation. 
Lignocaine and bupivacaine can both be used as infiltration to provide local analgesia. Lignocaine 
has a pH of 5 to improve its shelf life, and for this reason can be painful when injected. Warming thE­
solution to body temperature and injecting it very slowly can reduce the local stinging. Aspiration 
before each injection and constant movement of the needle are useful ways to avoid intravascular 
injections. This method of providing local anaesthesia is not popular in children (for procedures suci 














SEDAfiVES AS ADJUVANTS TO ANALGESIA 
Sedatives are particularly valuable when lengthy and repeated procedures are undertaken. 

Sedatives may result in unpredictable responses in some children who may become disinhibited, 

agitated, restless or over-sedated. 

Sedatives relieve anxiety, not pain. During their administration appropriate monitoring should be 

undertaken and skilled individuals should be available to manage the airway if a problem develops. 

Chloral hydrate is a pure sedative/hypnotic with no analgesic effect. Midazolam is an amnesic 

sedative, but also not an analgesic drug. These drugs should not be used alone for painful 

procedures. Ketamine may produce laryngospasm, particularly in infants. It is a potent analgesic as 

well as a dissociative anaesthetic. Ketamine can produce nightma~es and hallucinations, especially 






NSAIDS are very useful agents for pain management, either alone or in combination with other 
analgesics. Used in combination with an opioid, NSAIDS allow the use of a lower dose of opioid to 
achieve equivalent analgesia ('opioid-sparing effect'). They are also useful as a 
'step across' or a 'step down' analgesic when weaning a patient up or down the WHO ladder of pair 
control. 
One should be aware of the side effects and contraindications of the NSAIDS. NSAIDS are not 
licensed to be used in infants and should be used with care in this age group or in children weighing 
less than 10kg. They need to be used with care in children who are thrombocytopenic as they inhibi' 
platelet action. NSAIDS are especially good for pain with an inflammatory component, and for bone 















ADJUVANT ANALGESIC AGENTS 

NEUROPATHIC PAIN 
Neuropathic pain, which is usually due to nerve infiltration or compression, is only partially 
responsive to opioids. It should be considered particularly if the pain has an unusual nature, for 
example burning or shooting. 
Two classes of drugs are valuable in the management of neuropathic pain and should be started 
early on if possible: 
TRICYCLIC ANTIDEPRESSANTS 
Tricyclic antidepressants such as amitriptyline may be helpful, especially in treating the burning pair 
caused by nerve compression, invasion by tumour or from neuropathy (for example, caused by 
vincristine). The starting dose of amitriptyline is 500 micrograms/kg at night (increasing if needed to 
mg/kg twice daily). 
ANTICONVULSANTS 
Anticonvulsants such as carbamazepine may be helpful, especially when neuropathic pain is 
shooting or stabbing. Start with a low dose of 2,5mg/kg twice a day, and increase gradually by 2,5­
5mg/kg/h (consider using controlled release tablets). Therapeutic blood levels range from 4-14mg/1. 
NON-PHARMACOLOGICAL INTERVENTIONS 
ENVIRONMENTAL FACTORS 
The treatment room on a paediatric ward can often be a frightening place for a child. Every attempt 












I 'clinical' appearance and evidence of invasive instrumentation. The aim is to create an attractive 

environment decorated with toys, mobiles and pictures. 

SUPPORTIVE AND DISTRACTIVE TECHNIQUES 
I Age appropriate distraction strategies which may be used in the treatment room during procedures include: 
• Holding a familiar object (comforter), such as a pillow or soft cuddly toy 
• Singing; concentrating on nice things; telling jokes; games and puzzles 
• Going on imaginary journeys 
• Blowing out air or bubbles 
• Reading pop-up books 
• Playing With a kaleidoscope or 3D viewer 




• 	 looking in a mirror to see the view through a nearby window 
• 	 Watching television or a video, playing interactive computer games 
• listening through headphones to stories or music. 
Parents can assist with many of these activities. Not all children are helped by distraction; some 
prefer to focus on the procedure. It is important to identify each child's coping mechanism and help 
the child to use it. 
It is becoming more common for parents to stay with their child during an invasive procedure. 
However, this depends on the experience of the doctor and the type of procedure. less experience 
doctors are uncomfortable with parents present, and many doctors will allow parents to be present 
for venepuncture or lumbar puncture but would exclude them during more invasive procedures, for 












In one study almost all children between the ages of 9 and 12 years reported that the 'thing that 
helped most' was to have their parents present during a painful procedure. It is not enough just to 
allow parents to be present; they need guidance on how to support their child during the procedure 
Studies suggest that talking to and touching a child during a procedure is both soothing and anxie~ 
relieving. The child and parents should be adequately prepared for the procedure. Explaining to the 
parents why the procedure is needed, how it will be done and how long it will take may help reduce 
anxiety. 
In a few children, especially those who require repeated procedures and long stay in hospital, a chi! 
psychologist and/or a child psychiatrist form part of the valuable multidisciplinary team in oncology. 
Music and art therapy techniques may also be of value. 
RATIONALE FOR THIS STUDY 
Pain management does not appear in the textbook most recommended for South African 
undergraduate paediatric medical students. Hospitalised children with chronic pain are most likely tc 
be patients in a POU. In SA there is no formal unified regimen for pain control in children with 
terminal cancer. 
Pain in children is therefore managed according tothe experience and expertise of the paediatriciar, 
of the local POU. It is unknown what facilities are available or what methods are used by the differer 
POU's for pain management. Paediatric Oncology Units are responsible for all paediatric cancer 
management and for this reason it was decided to start a survey in this section of paediatrics. 
AIM 
The AIM of this study is to evaluate the present situation of pain management in the 9 POU's of SA 


















Study design: A cross-sectional study was used to assess the management of pain in the nine 

Paediatric Oncology Units (POU's) in SA. 







As a group, cross-sectional studies fall between purely descriptive studies and those that can be 
used for testing hypotheses. Cross-sectional studies are also useful for describing the clinical 
spectrum of a disease. However, in modified forms cross-sectional studies are sometimes employe 
to do some analYtical work. In cross-sectional studies all observations are made on a single 
occasion. Surveys are a form of cross-sectional study aimed at describing accurately the 
characteristics of a given population. They are often used for assessing attitudes, opinions or belief 
of persons concerning health related issues. The information is obtained by questionnaires and 
interviews. The questionnaire is an important device for gathering research data. In order to obtain 
accurate, valid and reliable responses it is necessary to have a well-designed questionnaire. A 
variety of comparisons can be made using survey data. Variables may need to be controlled. The 
researcher needs to measure differences between the groups. 
One great advantage with the self-administered questionnaire is financial. There is a marked 
reduction in costs because of savings in the number of interviewers to be employed, and in time. 
There is the additional advantage of standardized response, because the variability of different 
interviewing techniques and the interaction between the subject and the interviewer are eliminated. 
One problem with this method is that it can only be used in situations where literacy rates are 
sufficiently high and postal services are reliable. The disadvantages are higher rejection rates, the 






















1) Does a suitable questionnaire already exist? 

2) Who will complete the questionnaire? 

3) What format will be used? Open-ended and closed responses are the two major formats. 

Open-ended has the advantage of eliciting more detailed answers. The respondent is free to 
answer without any limitations imposed by the interviewer. The disadvantage is that greater 
time is taken to complete the questionnaire; respondents get tired; difficulty in analyzing 
answers. Closed response question have the advantage of being tightly structured; responsE 
is easy to code and analyze; less time is taken in filling the questionnaire. The disadvantage~ 
are that the answers have less depth. The respondent is led in pre-determined direction 
leaving him less choice to express his own potentially unique answers . 
o 	A questionnaire (Appendix 8) on the teaching and practical management of pain in children 
with terminal cancer was sent to each of the Paediatric Oncology Units in the RSA. Question 
26.1 and 26.2, on the teaching will not be dealt with in this research, but the information is 
included for future analysis. Open-ended and closed response questions were asked and at 
the end of the questionnaire there was enough space left for comments. 
An information sheet (Appendix A) accompanied the questionnaire. 
This method was suitable for this study: i) a" persons that completed the questionnaire are literate 











questions have the advantage of less time to complete the questionnaire iv) the questionnaire was 

completed at a paediatric congress which the 9 POU's attended. 

The information received from the POU's is confidential, patient identity or the name of the reportin~ 

unit is not revealed and no ethical issues apply to this study. 





The questionnaires were completed by the most experienced person from each POU. No previous 

questionnaires were used to collect any of the questions. 

There are only 9 POU's in SA and therefore the sample size was limited. Fortunately all 9 POU's 





QUESTIONS ASKED REPLY BY POU'S 
y N/AN 
• 72Do you use visual analogue scales for pain assessment?•Q1: 
6Do you use the 'by the ladder' approach for analgesic 3Q2: 
administration? 
4Do you use 'by the clock' analgesic management? 5Q3: 
Do you provide any info on cancer to the patients?Q4: 6 3 
Do you provide the parents with info about the side effects 7 2Q5: 
4Do you discuss the 'by the ladder' approach? 5Q6: 
Do you explain your choice of analgesic? 2Q7: 7 
2Do you have any input from parents? (e.g. pain assess men 4 3. Q8: 
Pain control) 












Q10: Do you use intravenous analgesic? 8 1 
Q11: Do you use SIC morphine syringe drivers? 4 5 
Q12:~YOU use intravenous syringe drivers? 7 2 
Q13: Do you use rectal suppositories for pain? 2 7 
• 1- morphine • 1 - Voltaren 
Q14: Do you use local anaesthetic before performing LP's 6 2 
• 1- not done 
• 1- EMLA 
• 1 - lignocaine 
• 1 - EMLA & lignocaine 
• 1 - IV sedation 
Q15: Do you use local anaesthetic before siting an IV cannula! 4 5 
14-EMLA 
Q16: Do you use sedation for intrathecal chemotherapy? 7 1 
• 1 - general anaesthetic 
• 1 - Dormicum & Vallergan forte & Inapsin 
• 1 - Ketamine 
• 1 - Dormicum 
• 1 - Dormicum & Ketalar 
• 1 - Midazolam & Valoron 
• 1 - Dormicum & Atropine & Ketalar 
• 1- not done 
Q17: Do you make use of a child psychiatrist to evaluate 4 5 
Emotional pain? 
Q18: Do you give accurate age-appropriate info about pain to th 6 3 
child? 
Q19: Do you find that situational factors can lead to inadequate 9 0 
pain control? 












I Q21: Do you measure/revise the child's pain regularly? 8 1 
• 6 - daily 
• 2 - 4 to 6 hourly 
Q22: Do you use the child's physical parameters as pain 4 5 
measure? 
Q23: Do you use Valoron drops? 9 0 
Q24: Do you use adjuvant analgesic drugs? 8 1 
• 1 - Corticosteroids/Anti-epilepticums 
• 2 - Steroids/Anti-depressants 
• 1 - Tegretol 
• 1 - Solucortef 
• 1 - Anti-depressants 
• 1 - Steroids/Tegretol/Amitriptilene 
• 1 ­ no drugs mentioned 
Q25: Do you make use of NSAIDS? 6 3 
• 1 - Doxyphene 
• 1 - Ponstan/Brufen 
• 1 - Voltaren 
• 1 - Brufen 
• 1 - Aspirin 
• 1 - drug not mentioned 
Q26: Do you feel you have optimal pain control for children? 7 2 
Q27: Do you make use of attention distractions? 1 8 
I 
Q28: Do you make use of music when performing procedures or 2 7 
for relaxation? 
Q29: Do you have a separate room to perform procedures and tc 9 0 













Over 80% of children with advanced cancer will experience pain, regardless of the underlying 
diagnosis. The child with cancer may experience pain of several etiologies (See table 1). 
Table 1: ETIOLOGIES OF PAIN IN CHILDREN WITH CANCER 
ETIOLOGY EXAMPLES 
Cancer-related 
• Direct • Bone andlor bone marrow invasion 
• Soft tissue invasion, capsular distension,' 
hollow viscus obstruction 
• Invasion/compression of central or peripheral 
nervous systems 
• Indirect • Bed sores 
• Debility • Infection 
Treatment-re/ated • Mucositis 
• Postoperative state 
• Infection . 
• Radiation dermatitis 
• Abdominal pain from protracted vomiting 
• Prolonged post-lumbar puncture headache 
• Neuropathy: drug-induced, phantom limb 
Procedure-related • Bone marrow aspiration and biopsy 
• Lumbar puncture 
Incidental • Trauma 
• Pre-existing medical condition 
Careful assessment of pain should be undertaken before commencing treatment. In 1987 Wong anc 
Baker described the QUESTT approach to pain assessment. 
• Question the child 
• Use pain rating scales 
• Evaluate behavioural and physiological changes 
• Secure the parents' involvement 
• Take the cause of pain into account 











Cognitive, physiological, sensory, behavioural, affective, socio-cultural and environmental factors a, 
effect pain assessment. 
The results of the questionnaire: 
The visual analogue scales are only used by two of the 9 POU's. 
Six of the 9 POU's make use of the 'by the ladder' approach, and 5 of the 9 POU's make use of thE 
'by the clock' analgesic approach. 
All professionals involved with any kind of pain management should use the 'by the ladder' approa' 
for analgesic administration. In SA two thirds of the POU's make use of the 'by the ladder' approact 
'By the clock' analgesic administration is used by 5 of the units. Analgesics given at regular times 'Iv 
provide consistent pain relief and prevent breakthrough pain. 
All the POU's avoid intramuscular analgesic administration and are aware that this method has a 
very limited role to play in the pain management of children. The intramuscular route is not 
appropriate and there is little place for 1M pain relief, particularly as a repeated treatment. 
Intravenous (IV) analgesics are used by 8 of the POU's. Four make use of subcutaneous morphine 
syringe driver and seven make use of an intravenous syringe driver. Two of the units use rectal 
suppositories. Local anaesthetic is used by four of the nine POU's before IV cannulation. 
A subcutaneous morphine syringe driver could be a very helpful method of managing pain in the 
terminally ill child, as it would allow some individuals to go home with a syringe driver. A hospice 
could be involved with the further care and management of these individuals. 
It appears that the POU's have good communication with parents and their patients. Information 
about pain, analgesic management and side effects of the treatment(s) is being discussed by most ( 
the units. Seven of them explain the choice of analgesics, and seven of the units give parents 
information on adverse effects of the pain treatment. Four of seven units have input from parents on 











The majority of the units use sedation before performing intrathecal chemotherapy. One unit does 
not administer intrathecal chemotherapy. 
Six of these units use local anaesthetic before performing lumbar punctures. These are very good 
results, but the units not using any anaesthetic or sedation should be encouraged to review their 
protocols and consider an appropriate form of sedation. 
A positive aspect from this survey shows, that the pain management teams are aware that 
contributing and situational factors can increase the level of pain in these children. 
Valoron drops (all 9 units use these drops) and adjuvant analgesic drugs (8 of the units use these 
analgesics) playa valuable role in pain management. 
Three of the POU's do not use NSAIDS. NSAIDS usually form part of STEP 1 of the 'by the ladder' 
approach. Thrombocytopaenia may be one reason why so few units IJse this group of drugs, but thi~ 
aspect was not determined in this study. 
Supportive and distractive techniques are of great value to limit the traumatic experiences of these 
children. These children need to deal with multiple procedures, for example IV cannulations, 
intrathecal chemotherapy, lumbar punctures and other investigations. 
Two units make use of music when performing procedures or for relaxation and only 1 unit makes 
use of attention distractions. All nine units have a separate room to perform procedures. Seven of 
the POU's feel they have effective, controlled pain management. Six of the 9 POU's provide the 
parents with information on cancer pain. Five of the 9 discuss the ladder approach. 












IMPLEMENTATION OF SELF-REPORT SCALES 
The selection of a self-report scale should be based on: 
• The age of the child 
• His/her cognitive ability 
• The time available for education about the scale 
• The knowledge of nursing staff about the scale 
• The preference of children who have used the different scales in the past. 
In practice very few, 2 of the 9 POU's, make use of a visual analogue scale. It may be that the 
paediatric units are too busy or that it simply takes too long for staff to explain and assess the child'E 
pain. It could be that the scales are too difficult or dull for patients to use. Cultural differences could 
also playa major role in POU's in SA. A pain scale should be equally applicable to all cultures, or at 
least allow modification for different cultural contexts. This problem is more obvious where visual 
scales are used with photographs of children's faces. Black children will not identify with photos of 
white children. In children between 3-6 years of age, a combination of verbal report and behavioural 
mechanisms is more reliable and a more accurate way for pain assessment. In children under the 
age of 3 years one has to rely only on behavioural mechanisms because communication is not 
primarily verbal. Scales selected should be simple, clear and easy to use. Self-report scales provide 
a subjective, quantitive measure of pain. They are generally considered suitable only for children 
over age 6 years of age, as they all rely to some extent on the child having some idea of relative SiZE 
and number. 
Self-report scales require the child's co-operation and understanding, and may be interpreted 
differently by different cultural groups. In practice they are said to be more useful in the assessment 











It is better to use one or two scales regularly and know them well, rather than several scales 
infrequently. Scales selected should be simple, clear and easy to use. Available scales for the self­
reporting of pain in children are listed in appendix C. The CHEOPS behavioural scale is easy to lea 
and use. Six observed behaviours, crying, facial expression, verbal expression, torso position, leg 
position and touch are scored. The CHEOPS scale was originally used for postoperative pain and 
needle pain. The disadvantage is that the scale is insensitive for long-term pain. 
Behavioural measures are the option to use in very young children (4 years or younger). The faces 
scale is a good option to use in the child 6-8 years old. The visual analogue scale (VAS) can be use 
in the child that understands numbers and proportions (age 5 years and over). The vertical scale 
may be better than the horizontal scale. 
Many children are incapable of completing a Visual Analogue Scale before they are 5 years old. 
Observation is therefore often the only way to establish whether a child is in pain and to measure th 
intensity of the pain. This is why it is important to find a system for clinical grading of child pain that 
could be implied by medical staff. The DEGR scale (Gauvain-Piquard A) includes anxiety and 
depression-like items. This scale was designed to diagnose and grade pain evoked by cancer in 
children aged 2-6 years. This scale is based on behavioural observation. 
The scale consisted of the following 17 items. 
ITEM SCALE 

1- Nervousness, anxiety 

2- Antalgic rest position 

3- Ability to protest 

4- Spontaneous protection of painful areas 

5- Child retires "into his shell" 

6- Somatic complaints 

7- Lack of expressiveness 

8- The child points out painful areas 













10-Antalgic behaviour during movement 
11-Lack of interest in surroundings 
12-Control exerted by the child when moved 
13-Slowness and rarity of movements 
14-Emotional reactions to medical examination of painful regions 
15-Signs of regression 
16-Social withdrawal 
17 -Tendency to cry 
Seven items concerned with pain (items 2,4,6,8,10,12 and 14), six items concerned with depressior. 
(items 5,7,11,13,15,and 16), and four items concerned with anxiety (items 1,3,,9 and 17). 
OBSERVATION OF PHYSIOLOGICAL MEASURES +/- BEHAVIOURAL CHANGE~ 
Only 4 of the 9 Paediatric Oncology Units evaluate physiological measures to assess pain. 
The following behavioural and physiological measures may be indicators of pain: 
• Facial changes, acute or chronic- for example frozen watchfulness 
• Crying 
• Sweating 
• Withdrawal from environment, not interacting and playing 
• Sleep disturbance 
• Poor appetite 
• Unwillinglless interested to play; decreased motor activity 
• Decreased concentration 
• Increased heart rate and blood pressure 














• 	 CONCLUSION 
There is no conformity in the management of pain in children with cancer by the 9 different POU's in 
SA. Some units have limited access to certain drugs. Cultural issues, language barriers and socio­
economic differences exist in some of these units. There are also limitations at some units for 
supporting services, such as hospice care. 
RECOMMENDATIONS 
There is a need for a formal unified regimen for pain control in children with cancer in SA. 

Guidelines should be available at every POU in SA. Physicians at these units, as well as the nursing 

staff and the rest of the multidisciplinary team involved with these children, should have teaching on 

pain management in children with cancer. 

Prior to treatment cancer pain should be classified according to the method proposed by Ljungman 





./ 	Cancer related (e.g. pain due to infiltration of the tumour in various organs or tissues) 
./ 	Treatment related (e.g. pain as side-effect of chemotherapy and radiation- for example, 
mucositis, radiation dermatitis, drug-induced peripheral neuropathy, prolonged post-lumbar 
puncture headache) 
./ Procedure related (e.g. due to finger-prick, venepuncture, lumbar puncture, bone marrow 
aspiration and trephine, or post-operative pain) 











SUGGESTED REGIMEN FOR PAIN MANAGEMENT IN SA 

It might not be possible to use the suggested regimen at all the POU's, but each unit could adapt U­
suggested regimen so that it would work best for their circumstances. Adaptations would need to b. 
made where some units have limited access to certain 'drugs, cultural issues and socio-economic 
differences exist and where supporting services (e.g. hospice) are limited. Each unit should review 
their guidelines and make the proper adjustments to have effective and controlled pain managemer 
for their children. The following are guidelines and recommendations to have optimal pain 
management control in children with cancer: 
1. 	 Make use of a PAIN ASSESSMENT TOOUSELF-REPORT.SCALE to assess the child's 
pain. The following are recommended: 
AGE MEASURE DESCRIPTION 
< 3 years CHEOPS Six observed behaviors: crying facial expression 
verbal expression, torso position, leg position, 
touch 
3 - 6 years Faces scale Faces indicating pain intensity were derived from 
children'S drawings 
> 6 years Visual analogUE 
scale (VAS) 
Vertical or horizontal line with verbal, facial or 
numerical anchors on continuum of pain 
intensity 




Child is asked about intensity, rhythm & variation 
pain 
Methods for assessment of pain 












• 	 Behavioural observational scales (see Appendix D) are the primary methods of pain 
assessment for neonates, infants, and children under four years of age or for children with 
• 
developmental disabilities. 
Behavioural scales may under represent the intensity of persistent pain, compared with self-reports. 
The CHEOPS (Children's Hospital of Eastern Ontario pain scale) was originally used for 
• 	 postoperative pain and needle pain. This scale is easy to learn and use. The one disadvantage is 
that it is insensitive to long-term pain. The CHEOPS scale (see Appendix E) is recommended and 
very practical to use. Behavioural scales do not on the whole depend on the child's desire or ability' 
communicate. The observational rating scale (DEGR scale) is also of value in children between2-6 
years. 
2. 	 Use the 'BY THE LADDER, BY THE CLOCK, BY THE MOUTH AND BY THE CHILD' key 
principles. 






MODERATE • 	 tabs &soluble tabs SOOmg • 	 10-20mg/kg 
• 	 Paediatric elixir 120mg/Smi • 	 Repeat 4-6 hourly 
• 	 Max SOmg/kg in 24 hours • 	 Suppositories 60mg. 12Smg. 
• 	 240mg & SOOmg 
IBUPROFEN • 	 not recommended <1 yr• 	 Tabs 200mg &400mg • 	 2.S-20mg/kg• 	 Suspension 100mg/Smi 
DICLOFENAC • 	 O.S-1mg/kg
• 	 Tabs 2Smg & SOmg • 2-3 times a day with food 




• 	 Codeine dose: O.S-2mg/kg• 	 4-6 hrly . SEVERE 
• 	 Syrup Smg codeine, 
120mgparacetamollSmi 













SEVERE MORPHINE • O,2-0,4mg/kg 4 hrly PO 
Increase the dose by 30-50% 
until the pain is controlled 
MST tablets or suspension • 
• 
Calculate MST dose at 6x4 hrh 
dose: 
=dose in 24 hours divided by 2 
=12 hourly MST dose 
MORPHINE SIC or 1M 
i I 
• O,1-0,2mg/kgldose 3-4 hourly 
Max dose 15mg 
A very effective analgesic regimen is to use valoron and paracetamol in alternating doses, giving 
each every 6 hours, but not together (e.g. valoron at 6 & 12 and paracetamol at 9 &3). 
VALORON (1 mg/kg/dose 6hourly: 1 drop =2,5 mg ). The weight of patient divided by 2,5 =numbel 
of drops per dose. The old regimen of giving 1 drop per year of age under-doses most children. OnE. 
drop per year of age +2 drops every 4-6 hourly is the suggested Valoron dosage. The maximum 
dosage should not exceed 1 mg/kg/dose. Valoron should not be us9ci in neonates and children unde 
10kgs outside of the hospital setting. 
4. 	 Use a STEPWISE PAIN MANAGEMENT. Multimodal treatment may be necessary. Start 
simple with the correct dose and step up if pain persists. For moderate to severe pain use 
paracetamol and valoron and then add NSAID if necessary (if no contra-indication present). 
5. 	 Appropriate analgesics for age, size of the child, procedure and illness should be used. 
6. 	 Use EMLAIAMETOP prior to cannulation, lumbar punctures, blood sampling. In some 
children where prolonged intravenous therapy is needed, a central venous line is advised. 
This can be done as a peripherally inserted long line. Broviac lines or port lines are 
recommended in children that will need long periods of chemotherapy. Topical anaesthetic 
cream (EMLA or Ametop) can be used to numb the port area before a needle is inserted for 
access. 
7. 	 Intrathecal chemotherapy can be a very frightening and painful experience for the child with 













not be possible at all the POU's. Effective sedation should be offered to limit the traumatic 
experience to the patient. Ketamine is a potent analgesic as well as a dissociative 
anaesthetic. Onset is rapid (1 min) and as is recovery ( 15-20 min) The dose for procedures 
is 1-4 mg/kg intravenously over a minimum of 60 seconds, to produce 5-10 min of 
anaesthetia. Midazolam and dormicum are also good choices, but unfortunately they only giv 
an amnestic sedative effect and are not analgesic drugs. Midazolam can also be given orally 
or intranasally using the injection solution at a dose of 400-500 microgramlkg. Onset is after 
15 min and recovery after 1 hour. The maximum dose is 15 mg and in heavier children 
temazepam may be a good alternative. In some children, midazolam causes respiratory 
depression and hyperexcitability. These can be reversed by flumazenil 10 microgram/kg. 
B. 	 Bone-marrow aspiration and trephine (biopsy) should be performed under general 

anaesthetic. If not possible Ketamine or Midazolam plus analgesic as advised above. 

Individualize every child. There is no final dose that will be appropriate for all children with pain. Th, 
'by the child' refers to the need to adjust analgesic doses based on the individual child. 
• 	 Medication should be administered to children by the simplest and most effective route, 
usually by mouth. Key principle, 'by the mouth', refers to the route of drug administration. 
Suggested pain regimen for procedures: 
PROCEDURE ANALGESIC DOSE 
Blood sampling Ametop I EMLA. If not available: ice 
Cannulation cube inside finger of a plastic glove 














Lumbar puncture Midazolam ! 100 - 200 microgramlkg IV l 
. If respiratory depression: use 10 microgram/kg 
flumazenil , . 
i 
Intrathecal chemo- General anaesthetic recommended 
• therapy If not possible: 
Bone marrow biopsy Ketamine 1-4 mg/kg IV over 60 at least seconds 
Premedication with oral atropine may 40 microgram/kg 




• 	 Practice verbal and non-verbal communication strategies, appropriate to children at variou 
developmental stages that may help the management of acute and chronic pain. For examplE­
./ Find something positive to say about an aspect of the child's physical state 
./ Give a message that the child can be helpful or can master something in his situation, for 
example, allow them to choose how they will lie or where their mother will sit 
./ 	Use a distraction approach: speak in terms of going home, or going playing after a painful 
procedure is over. 
./ Accept some crying or shouting, which can be a form of distraction for the child. 
For inpatient care, where possible, a comfortable bed or chair for the parent next to the child should 
be offered. In selected cases it may be appropriate for parent and child to sleep together in the samE 
bed. A majority of children sleep with their parents when they are ill at home and there is increasing 
evidence that it may have beneficial effects on the child. 
• 	 Communication with parents and patients form a very valuable and important part c 
pain management. The choice of drugs, side effects of treatment, and general 











• 	 Fear and anxiety, prior to and during painful procedures requires appropriate 
assessment. They exacerbate the experience of pain. Management of anxiety is 
therefore an essential part of pain management. The major drugs used to treat 
anxiety are the benzodiazepines. The commonest benzodiazepines used to treat 
anxiety are diazepam (long half-life), lorazepam (intermediate half-life) and 
midazolam (short half-life). Lorazepam has some amnestic effect, but it is 
midazolam that displays such an effect most consistently and effectively. 
• 	 The memory of the procedures, which were performed during a child's illness ofter. 
cannot be erased. The long-term adverse impact of repeated interventions in 
paediatric oncology is associated with cumulative experiences, as one painful and 
frightening procedure succeeds another, each made worse by the memory of the 
last and the fear of the next one. Drugs such as midazolam (100-200microgramlkg 
IV), that can attenuate the memory of an unpleasant procedure are useful. They 
must, however, never be used alone in the management of painful procedures, as 
they are not analgesic and their anxiolytic effect is very short-lived. 
• 	 CONSCIOUS SEDATION: the most widely used combination is that of midazolam, 
combined with morphine, fentanyl or ketamine. Ketamine may produce 
laryngospasm, particularly in infants. A trained anaesthetist or intensivist able to 
deal safely with upper airway obstruction should therefore administer the drug. 
• 	 Where deep sedation or general anaesthesia is unavailable or inappropriate, 











to make a child sleepy, and make it easier to perform procedures. They do very littl 
to modify anxiety caused by the procedure. 
Chloral hydrate is often used as sedation prior to performing minor procedures. The drug is 
administered orally but does not always have a pleasant taste, and can provoke nausea in 
some children. Furthermore, in older children the volume required. may be intolerable. ChiorE 
hydrate is contra-indicated in children with liver failure or renal impairment. 
ADJUVANT DRUGS 
Neuropathic pain 
Compression or invasion 
of central or 
peripheral nervous 
systems 
Tricyclic antidepressants, e.g. Amitriptyline, 
Carbamazepine 
Amitriptyline: SOO microgramsJkg at night 
Increase to 1 mgJkg twice a day if needed 
Carbamazepine: 2,SmgJkg twice a day and 
increase gradually by 2.S-Smg/kg/day at 
weekly intervals 
Maintenance dose: 10-20mgJkg/24hr 
Therapeutic blood levels range from 4-14mgll 
Corticosteroids. particularly dexamethasone 
Dexamethasone: 2S0-S00 microgramJkg/24hr 




in 3-S days 
Indicated for tumour­
asscociated raised ICP, 
cord compression. 




also be indicated for 
raised ICP 
Muscle spasm Benzodiazepines 
Diazepam: start with 100 microgramJkg every 
6-12 hr and titrate for effect 
Lorazepam or ox;aZEtpall1l 
are the drugs of choice; 
alternative is diazepam 
Widespread bone pain Corticosteroids 
Dexamethasone: as above 
High doses frequently 













The above suggestions are made keeping in mind the facilities available in the Republic of South 
Africa 
• REVIEW 
It is of great importance to review the patient as well as the pain management treatment for the 
individual on a regular basis. A pain assessment every 12 hours should be adequate to assure that 
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I am enrolled in the Palliative Medicine programme, MPhil degree 
through UCT, and would appreciate your input and help for my mini­
dissertation for this course. Prof G Wessels is acting as my 
supervisor. 
I would Iike to compare pain management regimens used by SA 
Paediatric Oncology Units. 
The aim of this research is to compare above regimens and comments 
on pain management in children with cancer and to suggest an optimal 
regimen for our local conditions. 
I will appreciate your input and time for this project. 
Attached you will find a questionnaire on pain management in children 
with cancer. 
Please be so kind to complete and fax to 021 - 9307382. 
Once again thank you for your interest and time. 












PAIN MANAGEMENT 	 APPENDIX 8 
Please be so kind to answer the following questions. 
Please answer the questions by choosing YES or NO 
The information that you provide will remain strictly confidential. 
At your centre: I YES INO 
1 Do you use visual analogue scales for pain assessment? . I 
2 Do you use the "by the ladder" approach for analgesic administration? 
3 Do you use "by the clock analgesic management"? 
4 Do you provide any information on cancer pain to the parents? 
4.1 	 Do you provide the parents with information about the adverse 
effects of pain Rx? 
4.2 	 Do you discuss the "by the ladder" approach? 
4.3 	 Do you explain your choice of analgesic? 
5 Do you have any input from parents? 
(eg. Pain assessment, pain control) 
6 Do you use intramuscular analgesics? 
7 Do you use intravenous analgesics? 
8.1 	 Do you use a SIC morphine syringe driver? 
8.2 	 Do you use an intravenous syringe driver? 
9 	 Co you use rectal suppositories for pain? If "YES" 
what do you use? 
10 Jc you use local anaesthetic before performing lumbar punctures? 
if "YES": what do you use? 
11 )c you use local anaesthetic before siting an IV cannula? 










IYES I NO 
12 	 Do you use sedation for intrathecal chemotherapy? 
If "YES": what drug(s) do you use? 
13 Do you make use of a child psychiatrist to evaluate 
emotional pain? 
14 Do you give accurate age-appropriate information about pain 
to the child? 
15 Do you find that situational factors can lead to inadequate pain 
control? (eg.cognitive, behavioural, and emotional factors) 
16 	 If yes, do you evaluate contributing situational factors? 
17 	 Do you measure I revise the child's pain plan regularly? 
If "YES" how often, ego Daily, 6-hourly, etc 
18 	 Do you use the child's physical parameters 
(eg. Heart rate, sweat index, blood pressure, cortisol level) 
as pain measure? 
19 	 Do you use Valoron drops? 
20 	 Do you use adjuvant analgesic drugs? 
(eg. Anti-depressants, anti-convulsants, Cortico steroids, 
neuroleptics, etc). If "YES" what do you use? 
21 Do you make use of NSAID's? 
If "YES" which NSAID(s) do you use? 
22 Do you feel you have optimal pain control for children? 

23 Do you make use of attention distractions (eg. "Pop-up" books, etc)? 













I YES I NO 

25 	 Do you have a separate room to perform procedures and to lessen 
tile traumatic experience of the cl-lild? 
26.1 Do you teach pain management in children to undergraduates? 
If "YES": For which year students (eg. ? II, ?III, ?IV, ?V, ?VI) 
How many periods in one year? 
26.2 Do you teach pain management in children to postgraduates? 
If "YES": Is it part of the official teaching program? 
Is the training during ward rounds? 
Please write short notes on the different drugs and dosages you use for pain control 
COMMENTS 












Appendix C SELF REPORT SCALES FOR PAIN ASSESSMENT 

Measure Description Indications for use Advantal.'es Disadvantages 
Self report measure Child is asked reo Intensity, 
rhythm and variations in pain 
Adequate cognitive and 
communicative abilities 
Simple, efficient, easily 
administered 
Subject to bias (e.g. demand 
characteristics, inaccurate or 
selective memory) 
Poker Chip Tool 
--------- ­
Faces scale 
Child chooses 1-4 chips 
(Chips = "piece of hurt") 
Age 4-8 years Correlates with overt 
behaviours during injections; 
adequate convergent validity; 
partial support for 
discriminant validity 
-------------- ­
Strong agreement among 
May seem childish to older 
children 
Younger child may tend toFaces indicating pain Age 6-8 years 
intensity were derived 1T0m children reo choose happiest face; may 
children's drawings Pain severity of faces and 
consistcncy or intcrvals. 
Adequate lest-retest 
also choose extremes 
Visllal analoglle scale Vertical or horizolllalline Age 5 years and older 
rt:I!!I~j!jt)' ......._. __ "­
Reliable and valid (child 
. -...­ ._--...__..__.....­ ....._...--... ­ ....- ­ .. -
Child must understand 
with verhal, lilcial or report correlates with proportional ity. 
numerical anchors on II bchaviourallllcusun:s and Intervals on lIumerical scales 
continuum of pain intensity with parent, nurse, physician 
ratings). Versatile (can rate 
different dimensions-pain 
and affect-on same scale) 
may not be equal from a 
child's perspective. Vertical 
scale may be better than 
horizontal. 




Age 3-12 years Reliabl~; adequate content 
validity; 
corelates with other scales. 
Pictorial plus numerical 
scales, so applicable to 










Appendix D BEHAVIOURAL SCALES FOR PAIN ASSESSMENT 

Mensure Description Indications for use Advantages Disadvantages 
Behavioural measures 
-~~~~~ ~~~-~~~ 
Procedural rating scale and 
observational scale of 
behavioural distress (OSBD) 
Direct observation of overt 
behaviours, usually measured 
repeatedly at regular 
intervals, according to time 
or phase of procedure 
10 observed behaviours: 
Crying, screaming, need for 
physical restraint, verbal 
resistance, requests for 
emotional support, muscular 
rigidity, verbal pain 
expression, flailing, nervous 
behaviour, information-
seeking 
Very young children. 
Used with self-report scale. 
Best reliability and validity 
are for short, sharp pain 
-----­
Originally used for bone 
marrow aspiration and 
lumbar puncture, but 
appropriate for any short, 
sharp pain 
Useful when child is unable 
to rate pain; less subject to 
bias than self report 
Not as well validated for 
longer lasting pain or for 
subtle behaviours (e.g. 
guarding wound). 
Difficult to discriminate 
Requires training of 
observers 
Satisfactory inter-rater 
reliability; OSBD correlates 
with self report of pain and 
anxiety 
Children's Hospital of 
Eastern Ontario pain scale 
(CHEOPS) 
Six observed behaviours: 
Crying, facial expression, 
verbal expression, torso 
position, leg position, touch 
Originally used for 
postoperative pain and needle 
pain 
Easy to learn and use. 
Inter-rater reliability = 80% 
concurrent validity 
Insensitive to long term pain 
Gauvain-Piquard rating scale 15 behaviours divided into 
three subscales: pain 
behaviours (e.g. guarding 
wound), anxiety behaviours 
(e.g. nervousness), 
psychomotor alterations (e.g. 
withdrawal) 
Validated with 2-6 year olds. 
Used for long term pain in 
children with cancer 
Preliminary studies show 
adequate inter-rater reliability 
and sensitivity to differences 
in children 











Appendix E Behavioural definitions and scoring of the CHEOPS scale to measure 
t f .pos opera lve paID 
Item Behaviour Score Definition 
Cry 1 No cry Child is not crying 
2 Moaning Child is moaning or quietly vocalising; 
Silent cry 
2 Crying Child is crying, but the cry is gentle or 
whimpering 
3 Scream Child is in a full-lunged cry; sobbing; 
may be scored with complaint or without 
complaint 
Facial 1 Composed Neutral facial expression 
2 Grimace Score only if definite negative facial 
expression 
0 Smiling Score only if definite positive facial i 
expression 
, Child verbal 1 ! None Child not talking 
1 i Other complaints Child complains, but not about pain; e.g. 
"I ant to see Mummy" or "I am thirsty" 
2 Pain complaints Child complains about pain ! 
2 Both complaints Child complains about pain and about 
other things; e.g. "It hurts; I want 
Mummy" 
0 Positive Child makes any positive statement or 
talks about other things without 
complaint 
Torso 1 Neutral Body (not limbs) is at rest; torso is 
inactive 
2 Shifting Body is in motion in a shifting or i 
se~entine fashion 
2 I Tense Body is arched or rigid 
i 
2 Shivering Body is shuddering or shaking 
involuntarily 
2 Upright Child is in vertical or upright position 
2 Restrained , Body is restrained 
Touch 1 Not touching Child is not touching or grabbing at 
wound 
2 Reach Child is reaching for but not touching 
wound 
2 Touch Child is gently touching wound or wound 
area 
2 Grab Child is grabbing vi~orously at wound 
2 Restrained Child's arms are restrained 
Legs 1 Neutral Legs may be in any position but are 
. relaxed; includes gentle swimming or 
serpentine-like 
2 Squirminglkicking Definitive uneasy or restless movements 
in the legs and/or striking out with foot or 
feet 
2 Drawn up/tensed Legs tensed and/or pulled up tightly to 
body and kept there 
2 Standing Standing, crouching or kneeling 











Patient leaflet: morphine 
QUESTIONS ABOUT MORPHINE 
Questions and concerns about medicines used to control pain are normal. We hope that this handout 

will answer your questions about your child's pain relief The medicines we use are safe and very 

effective. They will help your child recover more easily and quickly from his or her surgery. Ifyou 

have questions that are not answered in this handout, please ask to speak to one ofthe staff dealing 

with your child's pain management 

SOME COMMON QUESTIONS 

Is morphine too strong for children? 

Will my child become addicted to morphine? 

Will my child have unpleasant side effects from morphine? 

WHY DO WE USE MORPillNE? 

Your child may have some pain after certain procedures. 

Morphine and some morphine-like medicines are some of the most effective treatments to control this 

pain. These medicines are very safe when used properly. Your child should be able to move or cough 

without discomfort. Ifyour child is to have physiotherapy after surgery and has good control, the 

treatment will be more effective. Recovery and healing should take place more quickly. 

IS MORPHINE TOO STRONG? 

The pain relief effects of morphine depend on the dose given. In this hospital the doses are worked out 

for each child according to his or her weight and age. The children are watched carefully by the nurses 

and doctors in the wards. Special charts are filled in every hour by the ward nurses. These nurses 

check the dose of medicine that your child is receiving and how effective it is. As your child's pain 

gets less, he or she is given less medicine. 

CAN MORPHINE FOR PAIN CONTROL CAUSE ADDICTION? 

Your child will not become addicted to the morphine that he or she is given to control the pain. 













Wll.,L MY CHTI...D HAVE UNPLEASANT SIDE EFFECTS FROM MORPIDNE? 





Adjusting the dose of morphine. 

Giving other medicines to treat the side effects such as antisickness medicine. 

Over-sleepiness is rare and should not be confused with your child 'catching up' on sleep that he or 

she may have lost ifvery unwell before surgery. 

Wll.,L MY CHTI...D BE SORE WHEN MORPHINE IS STOPPED? 

We often give regular doses ofmiIder pain relief medicines, such as paracetamol or diclofenac, at the 

same time as morphine. These can be given as a tablet, syrup or suppository. They can help us to use 

less morphine and to stop the morphine sooner. When morphine is stopped, these milder drugs are 

given in adequate amounts to keep pain well controlled. 
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